PATHOPHYSIOLOGY, CLINICAL FEATURES, AND MANAGEMENT OF CHILDREN WITH CHRONIC INFECTIOUS DISEASES by Giannattasio, Antonietta
 UNIVERSITY OF NAPLES "FEDERICO II" 
 
 
Ph.D. Program  
“Human Reproduction, Development and Growth” 
XXII° CYCLE 
 
Director: Prof. Claudio Pignata 
 
 
 
Ph.D. Thesis 
 
PATHOPHYSIOLOGY, CLINICAL FEATURES, AND 
MANAGEMENT OF CHILDREN WITH CHRONIC INFECTIOUS 
DISEASES  
 
 
 
 
 
 
             Tutor                                                                  Student  
Prof. Alfredo Guarino                                  Dr. Antonietta Giannattasio 
 
 
 
 
 
Academic year 2009-2010 
 
  1 
INDEX 
CHAPTER 1 
Background 
 
Page 3 
1.1 Children with chronic diseases Page 4 
1.2 Goals of the thesis Page 8 
1.3 References Page 9 
  
CHAPTER 2 
Chronic viral hepatitis in childhood 
 
Page 13 
2.1 Management of chronic hepatitis B and C in children Page 14 
2.2 References Page 26 
2.3 Publications Page 30 
2.4 Liver steatosis in children with chronic hepatitis B and C Page 50 
2.5 References Page 58 
2.6 Publications Page 60 
  
CHAPTER 3 
Children with HIV infection 
 
Page 69 
3.1 Perception of disease and adherence to antiretroviral therapy in 
HIV-infected children   
 
Page 70 
3.2 References Page 87 
3.3 Publications  Page 90 
3.4 Psychosocial issues in children growing with HIV infection  Page 110 
3.5 References Page 119 
3.6 Publications Page 121 
  
CHAPTER 4 
Strategies to improve vaccination rates in children with 
chronic medical conditions 
 
 
Page 122 
4.1 Pneumococcal and influenza vaccination rates in children with 
chronic medical conditions 
 
Page 123 
4.2 References Page 139 
 2 
4.3 Publications Page 142 
4.4 Influenza and pneumococcal vaccinations in HIV-infected children: 
assessment of methological quality of current recommendations. 
 
Page 143 
4.5 References Page 155 
4.6 Publications Page 159 
  
CHAPTER 5 
Concluding remarks 
 
Page 160 
5.1 Conclusions Page 161 
  
CHAPTER 6 
Curriculum vitae and grants 
 
Page 164 
6.1 Curriculum vitae Page 165 
6.2 Grants Page 169 
  
 
 3 
CHAPTER 1 
 
 
BACKGROUND  
 
 4 
1.1 Children with chronic diseases 
 
 
1.11 Chronic viral hepatitis 
 
Among human hepatitis viruses, hepatitis B (HBV) and C (HCV) viruses are able to persist in 
the host for years and thereby causing chronic hepatitis. Three hundred and seventy and 130 
million people is estimated to be infected with HBV and HCV, respectively, worldwide (1). In 
endemic areas, HBV infection is often acquired perinatally or early in childhood and becomes 
chronic in a high proportion of cases. Universal vaccination of newborns has been effective in 
reducing the spread of infection. However, hepatitis B is still a social and health problem in 
underdeveloped areas where immunisation policies are unavailable, and even in developed 
countries, where the reservoir of infection is maintained by immigration and adoption. In 
some endemic areas children with chronic hepatitis B are also at risk for superinfection with 
the hepatitis delta virus (HDV), which worsens the prognosis of liver disease.  
HCV is not a less important problem. The prevalence of circulating anti-HCV antibodies in 
the pediatric population averaged 0.3% in Italy in the early 1990s (2), but a national 
observational study suggest that the number of “new” pediatric infections dropped by 
approximately 40% in 2000-2004 compared with the previous 5 years (3). The lower 
prevalence of HCV in children reflects the disappearance of transfusion-related hepatitis and 
the reduced efficiency of mother-to-child (vertical or perinatal) transmission, although the 
latter form of transmission is currently responsible for most “new” infections in the developed 
world and contributes to maintaining the reservoir of infection worldwide (4-7). This 
favourable epidemiologic trend is balanced, however, by the strong tendency of HCV 
infection acquired early in life (either perinatally or following blood transfusions) to become 
chronic (8-14). In the absence of a specific vaccination, HCV infection remains a major global 
health problem and HCV-related end-stage liver disease is still the most frequent indication 
for liver transplantation in adult patients.  
Chronic viral hepatitis acquired in childhood is a long-lasting process based on host-virus 
interaction, which may change over the years. A number of factors related to the virus 
(genotype, therapy), to the host (hormonal status, immunocompetence, therapy) and to the 
environment (alcohol, drugs, co-infections) affects the natural history of the disease, 
especially during adolescence and early adulthood. Strategies to improve the prevention and 
treatment of HBV and HCV infection, and the related liver disease in children, before the 
possible development of irreversible complications, should be investigated and implemented.  
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1.12 HIV infection 
 
Countries most heavily affected, HIV has reduced life expectancy by more than 20 years, 
hampered economic growth, and deepened household poverty (UNAIDS. Data from: 
www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp). 
Mother-to-child transmission (MTCT) is the main source of pediatric HIV-1 infection. MTCT 
of HIV-1 mainly occurs around the time of delivery, but breastfeeding is an additional route of 
viral transmission and accounts for about one-third of pediatric infections in resource-poor 
Countries (15). In the absence of antiretroviral therapy, about 30% of women transmit the 
virus to their infants. The estimated number of perinatally acquired AIDS cases in the United 
States peaked at 945 in 1992 and declined rapidly with expanding prenatal testing and 
implementation of appropriate preventive interventions (16). At the end of 2007, there were 2 
million children living with HIV around the world, an estimated 370,000 children became 
newly infected with HIV in 2007, and, of the 2 millions people who died of AIDS during 
2007, more than one in seven were children. Every hour, around 31 children die as a result of 
AIDS.  
HIV can affects a child‟s life through its effects directly on the child, on that child‟s family, 
and on the community within the child is growing up: 
- Many children are themselves infected with HIV 
- Children live with family members who are infected with HIV 
- Children act as carers for sick parents who have AIDS 
- Many children have lost one or both parents to AIDS, and are orphaned 
- An increasing number of households are headed by children, as AIDS erodes traditional 
community support systems 
- Children end up being their family‟s principal wage earners, as AIDS prevents adults 
from working, and creates expensive medical bills 
- As AIDS ravages a community, schools lose teachers and children are unable to access 
education 
- Doctors and nurses die, and children find it difficult to gain care for childhood diseases 
- Children may lose their friends to AIDS 
- Children who have HIV in their family may be stigmatized and affected by 
discrimination 
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In the last 10 years, dramatic advances in medical management of HIV infection have 
followed the results of clinical trials of antiretroviral combination therapies in children. The 
use of antiretroviral therapy during pregnancy in HIV-infected women has resulted in a 
dramatic decrease in the transmission rate to infants, which is currently less than 2% in most 
high-income Countries (17). In parallel, the introduction of highly active antiretroviral therapy 
(HAART) has changed the natural history of HIV-1 infection and the life expectancy of HIV-
1-infected adults (18,19) and children (20-26). Although in developed Countries children 
living with HIV infection are expected to live a long life, they still need to face major 
emotional burden, social stigma and global exclusion from the social contest (27).
 
Being a 
child or an adolescent with HIV implies major problems in terms of management of multiple 
drugs, adherence to antiretroviral therapy, drug resistance, quality of life, frequency at school 
and social interactions with peers (28).  
 
 
1.13 Immunization in at risk children 
 
Vaccinations programs are one of the greatest public health interventions of the last century 
and have dramatically improved quality of life (29). Benefits of vaccination to the individual 
include partial or complete protection against infections and symptoms of illness, improved 
quality of life, and prevention of up to 3 million pediatric deaths per year worldwide (29,30). 
Benefits of a universal vaccination program to society include creation and maintenance of 
herd immunity, prevention of disease outbreaks, and reduced health care costs (30). Despite 
the availability of safe and effective vaccines and substantial progresses in reducing vaccine-
preventable diseases, delivery to and acceptance of vaccinations by targeted populations are 
essential to further reducing and eliminating vaccine-preventable causes of morbidity and 
mortality (31). Children who are not vaccinated endanger public health representing a risk for 
other nonimmunized individuals, including subjects who cannot be immunized due to 
underlying health problems, and the small percentage of individuals in whom vaccination does 
not confer protection (29). They also contribute to increase health care costs (29). 
Access to immunizations, prevalence of vaccine-preventable diseases, and vaccination rates 
varies by geographic area or country. Throughout the United States and European Countries, 
immunization rates of children and adults are rising, but coverage levels have not reached 
established goals (32). As a result of low immunization rates, vaccine-preventable diseases 
still occur as evidenced by the measles epidemic, the large number of annual cases of 
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varicella, pertussis, and hepatitis B, and the more than 50,000 annual deaths in adults from 
influenza or pneumococcal infections (33-36). 
In an attempt to eliminate the risk of outbreaks of some diseases, governments and other 
institutions have instituted policies requiring vaccination for all people (compulsory 
vaccinations). For example, actual vaccination policies in most developed Counties require 
that children receive common vaccinations before entering school. In addition to compulsory 
vaccines, certain populations should receive additional vaccinations. Subjects with chronic 
medical conditions are at increased risk for severe complications related to vaccine-
preventable infections, such as influenza and pneumococcal infections (34,37). In Italy, 
compulsory vaccines are generally administered in vaccination centers and complementary 
vaccinations are actively offered to children with chronic conditions and are included in the 
Essential Levels of Care (38).
 
Despite long-standing recommendations to provide 
recommended vaccinations to children with chronic medical conditions, immunisation rates in 
these vulnerable populations remain poor (39). Several conditions hamper implementation of 
these vaccinations, including problems in identifying at risk children, ineffective 
organizational strategies and lack of awareness of disease severity or poor confidence by 
parents in specific recommendations (40,41). Often, the presence of a chronic condition is 
erroneously considered a contraindication rather than an indication to vaccination. 
It is important to ensure that patients comply with the vaccination schedule to the extent 
possible, and to provide education to parents who may have concerns about pediatric 
vaccinations.  
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1.2 Goals of the thesis  
 
In this PhD thesis, the organization and management of pediatric infectious diseases, with a 
perspective of public health, are investigated.  
Specific chronic diseases, as chronic viral hepatitis and HIV infection, have been selected as 
models to investigate the main aspects of prevention, management and treatment. The goal is 
to investigate the efficiency of organization and propose interventions with specific reference 
to treatment of infectious diseases, their direct and indirect results and how these conditions 
affect quality of life of at risk children and their families. 
The final goal of this research is to provide strategies to optimize public health system.   
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CHAPTER 2 
 
 
CHRONIC VIRAL HEPATITIS IN CHILDHOOD 
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2.1 Management of chronic hepatitis B and C in children  
 
 
2.11 Rationale 
 
HBV and HCV infections are the most common causes of infectious chronic disease 
worldwide, and are responsible of chronic hepatitis, cirrhosis, liver failure and hepatocellular 
carcinoma (HCC). Over the past two decades, the advent of universal immunization against 
HBV and the implementation of blood-donor screening for HBV and HCV have greatly 
decreased the rate of transmission; nevertheless, a considerable number of children and adults 
become chronically infected (1).  
The risk of developing chronic HBV infection after acute exposure is roughly inversely 
proportional to the age of the individual. Newborns of HBeAg-positive mothers have a greater 
than 90% risk of becoming chronically infected with HBV, children and adolescents have a 
25-50% risk, while only 5% of adults exposed to HBV develops chronic infection (2). Chronic 
hepatitis B is defined as persistence of HBsAg for longer than 6 months.  
In perinatally infected children estimated spontaneous clearance of HBV (i.e. loss of HBsAg 
and development of anti-HBs antibodies) occurs at a rate of 0.6% per year over the first 
decade of life, but the rate of clearance is higher, 1.8% per year, in patients infected as 
adolescents and adults (2). Of those children who remain infected, most develop “immune 
tolerance”, with  HBeAg-positivity, high serum HBV DNA but normal ALT levels. During 
the course of chronic hepatitis B, clearance of HBeAg represents a key event, because it 
implies that the host is no longer immunotolerant and enters a low replication phase (2,3). 
Among carriers with elevated ALT levels, the rate of clearance of HBeAg (seroconversion) 
averages between 8% and 12% per year. Seroconversion coincides with a decrease in serum 
viral load and biochemical and histological remission in the majority of cases (“inactive 
carrier state”) and may be followed by HBsAg seroclearance (2-4). Approximately 4% to 20% 
of inactive carriers have one or more reversions back to HBeAg. Among those who remain 
anti-HBe positive, 10% to 30% continue to have elevated ALT and high HBV DNA levels 
after HBeAg seroconversion (“HBeAg-negative chronic hepatitis B”). Clearance of HBeAg, 
whether spontaneous or after antiviral therapy, reduces the risk of hepatic decompensation and 
improves survival. 
Children with chronic HBV infection are usually asymptomatic and have normal growth, 
physical examination results, nutritional parameters and development (5). During childhood, 
chronic hepatitis B is a mild disease associated with a low rate of cirrhosis (6). However, 
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decompensated liver disease and HCC have also been reported in children (7-9). Pediatric 
HCC has a poor prognosis, with a long-term survival rate of only 10-30% (8). 
The goal of treatment for chronic hepatitis B encompass normalizing liver histopathology, 
suppressing viral replication and promoting immune-mediated clearance of HBV, and 
preventing the development of cirrhosis and HCC. Treatment options approved for children 
with chronic hepatitis B, interferon (IFN)-alpha, lamivudine and, recently, adefovir, do not 
achieve these goals in all treated patients (10-12).  
The main source of HCV infection is now perinatal transmission from infected mothers. 
Transmission is higher in mothers with high titres of HCV RNA and who are HIV positive, 
with a transmission rates varying from 2-12% depending on maternal infectivity (13,14). 
Children constitute a small proportion of the HCV-infected population. This favourable 
epidemiologic trend is balanced, however, by the strong tendency of HCV infection acquired 
early in life to become chronic (15-17). 
Chronically infected children are typically asymptomatic. Unlike with HBV, many patients 
with chronic hepatitis C have normal ALT levels despite necroinflammatory damage in the 
liver (18). Most children who are chronically infected with HCV have a milder disease with a 
more favourable natural course, compared to infected adults (16,19-22). Histological studies 
confirmed a prevalence of cirrhosis of 1.7% among 229 children with chronic HCV infection 
(20,23,24). Despite this favourable course, cases of HCV-infected children with cirrhosis who 
require transplantation have been reported (25-28). However, data about the severe course of 
pediatric HCV infection derive from studies performed in tertiary or quaternary referral 
centres and, consequently, do not provide an adequate perception of the real prevalence of 
worsening prognosis.  
In spite of the indolent course in the majority of cases, a substantial number of children with 
chronic hepatitis C have been treated with IFN. An analysis of published trials of IFN therapy 
in children with chronic hepatitis C has shown a favourable effect of therapy in terms of 
sustained response, mainly for patients who are infected with HCV genotypes other than 
genotype 1 (29). To date, the approved treatment for HCV-infected children older than 3 years 
of age is combination therapy with IFN-alpha plus ribavirin for 1 year (30,31). Treatment 
should be discontinued in children who still have detectable HCV RNA after 6 months of 
treatment because of the unlikely change of achieving a sustained response under these 
circumstances (31). Studies of IFN-alpha plus ribavirin have reported promising results with 
regard to a sustained response rate (32-35), but the real impact of treatment on long-term 
outcome remain to be established. Moreover, antiviral therapy is expensive, and its efficacy is 
tempered by several adverse effects and impairments in the health-related quality of life (36).  
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The management of chronic hepatitis B and C in asymptomatic children is still a challenge. As 
antiviral therapies are now available for the treatment of both infections, the knowledge of 
natural history of chronic HBV and HCV infections and appropriate evaluation of potential 
treatment candidates is crucial. 
 
We retrospectively investigated the long term outcome of chronic HBV and HCV infections in 
a large series of children who were observed regularly from childhood to young adulthood in a 
single care center. We compared treated and untreated children for clinical, biochemical, and 
virological outcomes. 
 
 
2.12 Experimental procedures 
 
Patients with chronic hepatitis B 
All children with chronic HBV infection observed for more than 5 years during the period 
1981-2005 at the Department of Pediatrics of the University “Federico II” were enrolled. At 
baseline, all patients underwent physical examination and liver function tests and were 
investigated for clinical history, risk factors for HBV infection, age at infection, clinical signs 
of liver disease, blood cell count, virological markers (i.e., HBsAg, antibody to HBsAg, 
HBeAg, anti-HBe, and serum HBV DNA levels), alfa-fetoprotein level, serum 
immunoglobulin level, and non-organ-specific autoantibody levels. Thereafter, all patients 
were monitored every 3-6 months by physical examination, liver function tests, virological 
tests, and alfa-fetoprotein level determination. At 6-12-month intervals, autoimmunity 
markers were determined for treated patients. Ultrasonographic examination of the liver, 
biliary tract, spleen, and portal vein was performed at 12-month intervals.  
Data on IFN treatment were collected. Complete response to therapy was defined as a 
decrease in transaminase levels (within the normal range), an HBV DNA level less than 10
5 
copies/mL, clearance of HBeAg, and development of anti-HBe within 12 months after 
stopping treatment (37). 
For untreated children, biochemical and virological aspects were monitored throughout the 
follow-up period. Inactive carrier state was defined as a detectable HBsAg level, an 
undetectable HBeAg level, a detectable anti-HBe level, a serum HBV DNA level less than 10
4 
copies/mL, and persistently normal ALT and aspartate aminotransferase levels. Resolved 
hepatitis B state was defined as previous HBV infection, with an undetectable HBsAg level, a 
normal ALT level, and an undetectable serum HBV DNA level (37).  
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Patients with chronic hepatitis C  
All children (age, 2-18 years) who had antibodies to HCV (anti-HCV) present for 16 months 
and who attended the liver unit at our hospital (University “Federico II”) during 1986-2004 
were enrolled. Patients who had concomitant systemic diseases or other causes of chronic 
liver disease were excluded from the study. For all patients, symptoms and health-related 
quality-of-life data were evaluated at each evaluation by clinical examination and an 
appropriate interview. Furthermore, all patients were evaluated at baseline for clinical history, 
risk factors for HCV infection, age at the time of infection, clinical signs of liver disease, liver 
function tests, complete blood cell count, serum HCV RNA level, HCV genotype, alfa-
fetoprotein level, serum immunoglobulin level, presence of non-organ-specific autoantibodies 
and crioglobulins, levels of thyroid hormones. Thereafter, all patients were monitored every 3-
6 months with physical examinations, liver function tests, virological tests, and determination 
of alfa-fetoprotein levels. At 6-12-month intervals, autoimmunity markers and hormone 
profiles were determined among treated patients. Ultrasound scanning of the liver, biliary 
tract, spleen, and portal vein was performed at 12-month intervals.  
 
Laboratory procedures  
At study entry and at each study visit, a serum sample was obtained from each patient and was 
stored at -80°C. Biochemical and virological tests were performed on fresh or frozen serum 
samples. 
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were 
evaluated using standard methods (upper limit of normal, 50 IU/L). 
HBV markers (HBsAg, anti-HBsAg, HBeAg, and anti-HBe levels) were measured using 
commercial immunoassay kits (Abbott Diagnostics). Serum HBV DNA level was 
quantitatively investigated, depending on the time, with a commercial hybridization method 
(cut off value, 5 pg/mL; Abbott Diagnostics) or with a commercial PCR assay (Amplicor 
HBV-Monitor kit; Roche Diagnostic System). 
The presence of anti-HCV was determined using a third generation ELISA (Ortho Diagnostic 
Systems). Quantification of HCV RNA level was performed by RT-PCR (COBASAmpliPrep/ 
HCV Monitor; Roche Molecular System; detection limit, 600 IU/mL of serum). In patients 
with serum HCV RNA levels less than the assay detection threshold, serum HCV RNA levels 
were determined using a PCR-based test (Amplicor; Roche Molecular System; detection limit, 
50 IU/mL) (38). Genotyping was performed by analyzing PCR products with a reverse-
hybridization assay (Inno LiPA HCV II; Innogenetics) (39). 
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Histological evaluation 
Liver biopsy specimens, obtained after receiving informed consent from parents or legal 
guardians, were analyzed by the same liver pathologist, who was blinded to clinical and 
biochemical data. Specimens were scored with regard to hepatitis activity (grades, 0–18) and 
fibrotic changes (stages, 0-6), according to Ishak et al. (40).  
 
Statistical analysis 
All data are expressed as medians and ranges. Comparison of categorical variables was 
performed using the x
2
 test or Fisher‟s exact test, as appropriate. Comparison of continuous 
data was performed using the Mann-Whitney U test and the Kruskal-Wallis test. A p value of 
less than 0.05 was considered to be statistically significant. 
 
 
2.13 Results 
 
Chronic hepatitis B 
One hundred eight consecutive patients (65 males; median age at last observation, 17.9 years; 
range, 6-34.2 years) observed over a period of up to 24 years were enrolled in the study. The 
course of chronic hepatitis B was evaluated for a median period of 12.1 years (range, 5-23 
years). 
A total of 57 liver biopsy specimens were obtained from 37 treated and 20 untreated children. 
Histological assessment revealed the presence of mild to moderate disease in most patients. In 
particular, 33 children (57.9%; 19 treated and 14 untreated; p>0.05) had minimal hepatitis, 
and 19 patients (33.3%; 14 treated and 5 untreated; p>0.05) had moderate hepatitis. Severe 
hepatitis was present in 4 patients (7.1%; 3 treated and 1 untreated; p>0.05), and features of 
micronodular cirrhosis were detected in one child (1.7%; an 8-year-old boy with unknown 
duration of disease who subsequently received IFN-alpha treatment).  
During the observation period, 67 children remained untreated, and 41 were treated with IFN-
alpha. After a median period of observation of 12.1 years (range, 5-23 years), HBeAg loss and 
serum HBV DNA clearance occurred in 43 untreated patients (69.3%) who were HBeAg 
positive at study entry and in 33 treated children (80%; p>0.05). In addition, 6 untreated 
patients (9.7%) and 4 treated patients (9.7%) became HBsAb positive at the end of the follow-
up period.  
No patient developed end-stage liver disease or hepatocellular carcinoma. 
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Chronic hepatitis C 
A total of 67 children with chronic hepatitis C without other underlying systemic diseases (31 
males, median age at liver biopsy 8.6 years, range 2-15; median duration of HCV infection 7.2 
years, range 2-15) were enrolled.   
On the basis of ALT levels during the first year of anti-HCV positivity, children were divided 
in 2 groups: those with hypertransaminasemia (100 patients, all of whom had detectable HCV 
RNA) and those with normal ALT values (25 patients). Of the 100 patients with 
hypertransaminasemia, 50 were treated with IFN during the period of observation. 
At baseline, treated patients, untreated patients with hypertransaminasemia and untreated 
patients with normal ALT levels were comparable with regard to age, sex, clinical features, 
duration of HCV infection, and distribution of HCV genotypes. 
All patients remained symptom free throughout the period of observation, with the exception 
of IFN-related adverse effects among the treated patients. No patient showed signs of hepatic 
decompensation. 
Treated patients 
Twenty-eight children had received IFN recombinant alpha-2b (5 MU/m
2
 3 times per week for 
12 months), 9 children had received IFN recombinant alpha-2a (5 MU/m
2
 3 times per week, 
with durations of 6 months in the presence of a genotype other than 1b and of 12 months in 
presence of genotype 1b), and the remaining 13 children had received IFN alpha-
lymphoblastoid (3 MU/m
2
 3 times per week for 12 months). The median duration of 
observation for treated children was 8.9 years (range, 4.9-14.4 years). Response to IFN 
treatment according to HCV genotype is reported in figure 1. 
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Figure 1. Flow diagram of the outcome in 50 treated children with chronic hepatitis C  
50 treated children with
chronic hepatitis C
Genotype 1: 
33 (66%) patients
Genotype other than 1: 
33 (66%) patients
Sustained virological
response: 
8 (24%) patients
Sustained virological
response: 
11 (65%) patients
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Untreated patients  
Median duration of observation was 9.2 years (range, 3.4-14.9 years) in 50 untreated patients 
with basal hypertransaminasemia and 7.9 years (range, 4.3-14.2 years) in 25 untreated patients 
with normal ALT levels at baseline. 
The behaviour of ALT and HCV RNA in 75 untreated children at the end of observation 
period is reported in figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Flow diagram of the outcome in 75 untreated children with chronic hepatitis C  
75 untreated children with
chronic hepatitis C
25 patients with normal
ALT at baseline
6 (12%) patients:
Normal ALT
HCV RNA negative
At the end of follow up:
10 (20%) patients:
Normal ALT
HCV RNA positive
34 (68%) patients:
Abnormal ALT
HCV RNA positive
50 patients with
abnormal ALT and 
HCV RNA positive at 
baseline
9 patients with
HCV RNA negative
12 (75%) patients:
Normal ALT
HCV RNA positive
4 (25%) patients:
Fluctuating ALT
HCV RNA positive
16 patients with
HCV RNA positive
At the end of follow up:
Same status at the end 
of follow up
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All children remained anti-HCV positive during the entire period of observation. At the end of 
the follow-up period, rates of HCV RNA clearance and ALT normalization were significantly 
higher in treated (38%) than in untreated children (12%; p <0.05). 
Histological evaluation 
A total of 64 patients (median age, 8.2 years; median duration of HCV infection, 6.9 years) 
underwent liver biopsy to assess the extent of liver damage and to guide management and 
treatment. Liver biopsy was performed for 47 of 50 treated children ≤6 months before 
commencement of treatment and for 17 of 75 untreated children. At the time of liver biopsy, 
all patients had viremia and hypertransaminasemia, with the exception of a girl who had a 
normal transaminase level. The median hepatitis grade was 4.4 (range, 1-8), and the median 
fibrosis stage was 1.6 (range, 0-4). No cases of cirrhosis (i.e., fibrosis scores of 5 or 6) were 
observed. The age of patients at the time of biopsy and the duration of HCV infection did not 
correlate with fibrosis score.  
Twenty-one out of 50 treated children received a second liver biopsy at a median period of 5.5 
years after the initial histological evaluation (range, 2-11.2 years). In 6 patients with sustained 
virological response, the hepatitis grade improved in all patients (from a median value of 5.5 
to 2.2), and the fibrosis stage decreased in all children but 1 (83%), in whom fibrosis did not 
change (score 1). In contrast, of 15 non responders, the hepatitis grade improved in 4 children 
(26.7%); the fibrosis stage improved in 6 patients (40%), did not change in 5 patients (33.3%), 
and worsened in 4 cases (26.7%). In the group of non responders who had worsening fibrosis, 
only 1 HCV genotype 1b-infected obese child was found to have cirrhosis at the second 
biopsy, which was performed 7 years after the first biopsy and 13.1 years after the acquisition 
of HCV infection. 
These data have been extensively presented and discussed in a previously published study 
(41). 
 
 
2.14 Discussion 
 
Children with chronic hepatitis B and C mostly remain symptom free, experience normal 
growth, and do not show clinical signs of chronic liver disease. A proper knowledge of natural 
history and identification of individuals who would benefit from therapy are mandatory. Our 
research contributes information regarding the long-term outcome of chronic hepatitis B and 
C acquired in childhood. During the entire period of observation, no child had decompensated 
liver disease or required liver transplantation.  
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Cirrhosis and HCC due to chronic HBV and HCV infection have been described to occur 
rarely during the pediatric age and more frequently during the second decade of life (7,9,25-
28,42). In our series, only 1 patient with chronic hepatitis B had histological signs of cirrhosis, 
and none of the patients developed HCC. Because follow-up biopsies were not systematically 
performed in our study, it is possible that the progression to compensated cirrhosis could have 
been missed. However, strict investigation using ultrasonographic examination did not reveal 
features of severe liver damage in any of the patients. Among patients with chronic hepatitis 
C, histological evaluation revealed a morphologically benign disease in the majority of cases, 
a relatively slow progression of fibrosis and an extremely rare cirrhosis. The analysis of paired 
liver biopsies performed in a subgroup of children revealed a relatively slow progression of 
fibrosis. Unlike what has previously been reported (43), no linear correlation between duration 
of disease and progression of fibrosis was found in the present study. In fact, 2 of the 3 HCV-
infected children with moderate fibrosis (score, 4) at the time of the first biopsy had a short 
duration of disease (2.1 and 2.5 years). On the other hand, the only patient for whom fibrosis 
was absent had a disease duration of 13.9 years. Therefore, the severity of liver disease does 
not seem to depend on the duration of HCV infection; instead, a host-virus interplay might be 
involved.  
Several studies involving adults with chronic hepatitis B have shown that the long term 
outcome in patients after IFN-related HBeAg seroconversion is favourable in terms of HBV 
clearance, reduction of HCC, and prolongation of survival (44,45). Similarly, there is evidence 
that spontaneous seroconversion induces sustained remission in the majority of cases (4). 
Although it has been reported that IFN-alpha therapy accelerates HBeAg seroconversion in 
children (11), it is still not known whether faster seroconversion can modify the natural 
history of the disease. In our series, 66% of treated children and 55% of untreated patients 
with detectable HBeAg levels seroconverted to anti-HBe and had serum HBV DNA levels 
less 10
5
 copies/mL at the final evaluation; 8% of the patients achieved a detectable anti-
HBsAg level. No advantage at final evaluation in terms of normalization of ALT levels, 
clearance of HBV DNA, and seroconversion was observed in treated patients compared with 
untreated, confirming that IFN-alpha therapy accelerates only seroconversion to anti-HBe. 
Although seroconversion seems to also confer favourable outcomes in children with HBV 
infection, Bortolotti et al. (46) reported 2 cases of HCC, 9 and 16 years after seroconversion. 
The possibility of spontaneous late reactivation and the occurrence of cirrhosis and HCC in 
patients with undetectable HBeAg and HBV DNA levels suggest that long-term surveillance 
is necessary for all patients with chronic hepatitis B, including inactive carriers and patients 
who do not have cirrhosis (47). 
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As for chronic hepatitis C, in our study the rate of spontaneous viral clearance in untreated 
children (12%) was lower than that reported by Vogt (45%) (21) and Locasciulli (26.8%) (22). 
This discrepancy could be related to the peculiar characteristics of patients included in those 
studies: the first included children who had post-transfusion HCV infection without clear 
evidence of chronic hepatitis, and the second evaluated patients who had leukaemia that was 
in remission and an atypical serological profile for HCV infection. Thus far, no predictive 
factor (including HCV genotype) of spontaneous viral clearance has been identified; it is 
likely that genetically determined immunological factors could be involved. Treated children 
with chronic hepatitis C had a rate of sustained virological clearance significantly higher than 
that for untreated children; in particular, this occurred in the presence of genotypes other than 
genotype 1. These findings confirm the previously reported favourable effects of IFN therapy 
(29). Presently, combination therapy using pegylated IFN and ribavirin has dramatically 
improved the sustained virological response among adults with chronic hepatitis C (30); 
preliminary studies have confirmed the efficacy of this therapy for children as well (48). 
Compared with previous studies (29), our study had a longer period of observation, both for 
treated and untreated patients. Despite the longer post treatment follow-up period, in our 
patients the rate of relapse was lower (8% vs. 22%). This discrepancy is probably attributable 
to the very strict response criteria used in our study, in which frequent determinations of 
serum HCV RNA level were performed.  
A careful understanding of the natural history of HBV and HCV infections in children is 
important in making decisions regarding treatment. One of the most debated questions is 
whether treatment can modify the long-term course of chronic hepatitis B. According to 
current guidelines, children 2 to 17 years of age who are HBsAg seropositive for more than 6 
months with persistent elevation of ALT levels >2xULN and evidence of active viral 
replication (positive HBeAg, HBV DNA levels >10
5
 copies/ml or 20000 IU/ml in their serum) 
for more than 3 months should be considered for therapy (3). Treatment with IFN or 
lamivudine should be considered, but the side effects of IFN and the emergence of viral 
mutants mean that neither is ideal except for compassionate use. Adefovir is not sufficiently 
effective in children, but has the advantage of less viral resistance. Future therapies may hold 
more promising for HBV-infected children. Treatment for chronic hepatitis C obtains better 
results especially in presence of genotype other that 1. However, at the present time, all 
children with chronic hepatitis C do not seem to be reasonable candidates for such therapy, 
because treatment is expensive, prolonged and is associated to several adverse effects. 
Furthermore, in the vast majority of untreated children, no significant worsening is usually 
observed in our study. 
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In conclusion, this study indicates that chronic hepatitis B and C acquired in childhood are 
mild diseases with a slow progression of fibrosis. Considering the treatments available for 
chronic hepatitis B, it seems reasonable to not treat all children, but to treat only those with  
more-severe liver disease and/or with positive predictive factors of response. Treatment of 
children with chronic HCV infection has provided more promising results. 
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2.4 Liver steatosis in children with chronic hepatitis B and C 
 
 
2.41 Rationale 
 
Hepatic steatosis is defined as fat deposition in the liver, with more than 5% of hepatocytes 
containing fat deposits. Hepatic steatosis may contribute to liver disease increasing sensitivity 
to oxidative stress and cytokine-mediated hepatic damage (1). The causes of fatty liver in 
children are enumerable as compared to adults and can be divided into hepatic and non-
hepatic (2,3). Chronic hepatitis B and C have been frequently associated with hepatic 
steatosis. The frequency of steatosis in adults with chronic hepatitis B ranges from 18 to 76% 
while in chronic hepatitis C it is between 31 and 72% (4-8).  
While the pathogenesis oh hepatic steatosis in chronic hepatitis B seems to be related to 
metabolic factors, in chronic hepatitis C viral factors (HCV genotype 3) play a role, in 
addition to obesity, dyslipidaemia and insulin resistance (6,8). Evidences supporting the direct 
steatogenic role of HCV include the positive correlation between the presence and severity of 
steatosis and the viral load and the reduction of steatosis in presence of a sustained response to 
antiviral therapy (clearance of serum HCV RNA) (9-11). Hepatic steatosis impacts on the 
degree of inflammation and fibrosis and may influence the long-term prognosis of chronic 
hepatitis C (8,12,13). 
Data on the prevalence and significance of hepatic steatosis in children with chronic hepatitis 
B and C are scarce. Furthermore, the role of host-viral interactions might be better understood 
in children since they haven‟t so many co-factors responsible for steatosis such as alcohol 
intake, dyslipidaemia, insulin resistance, type 2 diabetes or metabolic syndrome as adults 
have. 
 
Aim of this research was to investigate the prevalence of histological evidence of hepatic 
steatosis at liver biopsy in pediatric patients with chronic hepatitis B and C. Further, we 
investigate the correlation between hepatic steatosis and clinical, viral, metabolic and 
histological factors. 
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2.42 Experimental procedures 
 
Patients  
A total of 120 consecutive otherwise healthy children with chronic HBV infection (56 
patients) or chronic HCV infection (64 patients) who underwent liver biopsy for diagnostic 
purposes at the Pediatric Liver Unit of the University Federico II were enrolled. 
Diagnosis of chronic hepatitis B was based on the presence of HBsAg in serum for 6 months 
or longer. Diagnosis of chronic hepatitis C was based on the presence of serum anti-HCV 
antibodies and HCV RNA lasting more than 6 months.  
Exclusion criteria included the presence of concomitant systemic diseases, concurrent 
infection with major hepatotopic viruses or HIV, or presence of other liver disease. Patients 
with thyroid diseases, malnutrition, diabetes, dyslipidaemia, exposure to hepatotoxic drugs or 
alcohol were also excluded from the study. None of the patients had received antiviral 
treatment before liver biopsy. 
The database and the medical records were used to retrieve the following information: 
demographic data, primary risk factors for HBV or HCV infection, year of infection, clinical 
features with particular regard to the presence of hepatomegaly, splenomegaly, signs of 
hepatic decompensation, anthropometric and laboratory data. As for anthropometric data, 
height, weight and body mass index (BMI), calculated as Kg/m
2
, were evaluated at the time of 
liver biopsy. Overweight was defined by BMI  90th percentile for age and obesity by BMI  
95
th
 percentile for age, according to CDC standards (14). For each patient the following 
laboratory evaluation was performed at or near the time of liver biopsy: aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase 
(GGT), alkaline phosphatase, albumin, prothrombine time, international normalized ratio, 
blood cells count, fasting plasma glucose, insulin, cholesterol and triglycerides serum levels, 
as well as viral markers (for children with chronic herpatitis B: HBsAg/HBsAb, 
HBeAg/HBeAb, serum HBV DNA; for children with chronic hepatitis C: serum HCV RNA).  
For patients with chronic hepatitis C who had received antiviral therapy after liver biopsy, the 
correlation between the presence of hepatic steatosis and response to therapy was also 
analyzed. A sustained response to treatment was defined as absence of serum HCV RNA after 
24 weeks following the end of therapy. 
Patients were included in the present study if anthropometric, clinical, laboratory and 
histological data were complete. 
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Laboratory procedures 
Liver function tests, fasting glucose, cholesterol and triglycerides were measured by standard 
laboratory methods. Biochemical and virological tests were performed on fresh or frozen 
serum samples.  
HBV markers (HBsAg/HBsAb, HBeAg/HBeAb) were measured using commercial 
immunoassay kits (Abbott Diagnostics, Chicago, IL, USA). Serum HBV DNA was 
quantitatively investigated, depending on the time, with a commercial hybridization method 
with a cut-off value of 5 pg/ml (Abbott Diagnostics, North Chicago, IL, USA) or with a 
commercial PCR assay (Amplicor HBV-Monitor kit, Roche Diagnostic System, NJ, USA). 
Anti-HCV antibodies were tested by an enzyme-linked immunosorbent assay (ELISA, third-
generation). HCV RNA was measured by quantitative RT-PCR method (Amplicor Monitor, 
Roche Diagnostics) with a detection limit of approximately 600 IU/ml serum. HCV 
genotyping was performed with a second-generation reverse hybridization line probe assay 
(Inno-Lipa HCV II, Innogenetics) following the manufacturer‟s protocol.  
Insulin resistance was calculated from fasting plasma insulin and glucose by the homeostasis 
model assessment (HOMA) method proposed by Matthews (15). 
 
Histological evaluation 
Liver specimens were formalin-fixed and paraffin embedded for histological evaluation. 
Histological analysis of the liver sections was performed by two experienced pathologists 
blinded to the clinical data. Liver histology was evaluated according to Ishak scoring 
(necroinflammation score: 0-18, fibrosis score: 0-6) (16).
 
Hepatic steatosis was graded 
semiquantitatively by determining the percentage of affected hepatocytes according to the 
Brunt classification: grade 0 (<5% of hepatocytes involved), grade 1 (5–33% involved), grade 
2 (34–66% involved), grade 3 (>66% involved hepatocytes) (17,18). 
 
Statistical analysis  
Statistical analysis was performed using a statistical program package (GraphPad Instat 3 
Software). Descriptive data were expressed as median and range or mean and standard 
deviation (SD). Clinical, laboratory and histological differences between groups were assessed 
using the Mann-Whitney test (continuous variables) or chi-square test (categorical variables). 
Correlation analysis was performed by the Spearman test as appropriate. For all tests, results 
with p values less than 0.05 were considered statistically significant. 
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2.43 Results 
 
Children with chronic hepatitis B 
All 56 patients (median age 8.1 years, range 2.2-17.3) were symptom free and none of them 
have decompensated liver disease. All patients were HBsAg positive at the time of liver 
biopsy, 48 (85.7%) patients were HBeAg positive at the time of liver biopsy, 3 (5.4%) patients 
had already obtained spontaneous seroconversion to HBeAb, in 5 (8.9%) cases HBeAg status 
was unknown. All but two patients had detectable HBV DNA in serum at the time of liver 
biopsy. In children with detectable viremia, median serum HBV DNA was 104710 copies/ml 
(range 330-854660). 
Fifty-five (98.2%) patients had fibrosis at liver biopsy while one child had no fibrosis; the 
stage of fibrosis was 1 in 19 (34.6%) children, 2 in 30 (54.5%) cases, 3 in 3 (5.4%) cases and 
4 in one (1.9%) child. Two (3.6%) patients had histological evidence of micronodular 
cirrhosis (fibrosis score 5). 
Fifty-four patients had no steatosis at liver biopsy; steatosis was present only in 2 (3.6%) 
children (grade 1 in both cases). Features of patients with steatosis are reported in table 1. 
Twelve (22.2%) of 54 patients without steatosis and both (100%) patients with steatosis were 
overweight (6 and 1, respectively) or obese (6 and 1, respectively) (p=0.059). Relative BMI 
did not statistically differ between the two patients with steatosis (126.4±1.2) and 12 
overweight/obese children without steatosis (125.7±12.3). 
Mean relative BMI was significantly higher in 2 patients with steatosis compared with the 
whole group without steatosis (p=0.04). 
No significant difference between patients with and without steatosis was found with regard to 
demographic parameters (age, sex, route of HBV infection) and biochemical features (fasting 
glucose, triglycerides, cholesterol, ALT values, GGT values). Further, serum HBV DNA 
levels, HBeAg positivity and histological features did not significantly differ between the two 
groups. 
 
Children with chronic hepatitis C 
All 64 patients (median age 8.3 years, range 2.5-14) with chronic hepatitis C were symptom-
free and none of them have a decompensated liver disease. Among the studied children, 16 
(25%) had hepatic steatosis on liver biopsy specimen. In particular, steatosis was mild in 10 
(62.5%) patients and moderate in the remaining 6 (37.5%) children. None of the patients had 
signs of severe steatosis. Steatosis was macrovescicular and located in the periportal area 
rather than in the centrilobular area. Histopathologic features of nonalcoholic steatohepatitis 
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such as perisinusoidal and perivenular fibrosis and ballooned hepatocytes were absent. 
Features of children with steatosis are reported in table 1. 
Clinical, laboratory and histological features at liver biopsy were compared in children with 
and without steatosis and no difference was found between the two groups.  
The most represented HCV genotype was 1b in both groups (24 children without and 8 with 
steatosis). Five (10.4%) children without steatosis and 3 (18.7%) with steatosis were 
overweight, while 5 (10.4%) patients without steatosis and 3 (18.7%) with steatosis were 
obese (p>0.05).  
Although no significant difference in the necroinflammatory and fibrosis scores was found 
between children with and without steatosis, it is to note that 3 (18.7%) out of 16 patients with 
hepatic steatosis had a fibrosis score > 2 with respect to 1 out of 48 patients without steatosis 
(2.1%, p<0.05). It is also to note that these 4 patients were the sole subjects having a more 
severe degree of fibrosis (fibrosis score 3 or 4), while in the remaining 60 children the fibrosis 
score ranged from 0 to 2.  
Non-parametric correlation analysis showed that the severity of steatosis, expressed by 
steatosis score, significantly correlated with both ALT (r=0.27, p<0.05) and GGT (r=0.25, 
p<0.05). No relationship was found with relative BMI, HOMA or duration of HCV infection 
(p>0.05). 
Only 3 children (2 without steatosis and 1 with steatosis) had GGT value over the normal 
range for age (1.7, 2.2 and 1.7 times the upper normal value, respectively), 4 children (3 
without and 1 with steatosis) had cholesterol serum level upper the normal value (1.2, 1.05, 
1.08 and 1.05 times the upper normal value, respectively), while no patient had 
hypertriglyceridemia. 
Forty-seven children (34 patients without and 13 with steatosis) received a course of IFN 
therapy at standard dosage after liver biopsy. A sustained response was observed in 18 (53%) 
out of 34 treated patients without hepatic steatosis and in 3 (23%) out of 13 treated children 
with steatosis (p>0.05).  
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Table 1. Features of children with chronic hepatitis B and C and presence of steatosis at 
liver biopsy 
 Patients with chronic 
hepatitis B and steatosis 
(n=2) 
Patients with chronic 
hepatitis C and steatosis 
(n=16) 
Males 2 (100%) 7 (44%) 
Median age in years (range) 9.3 (5.6-13) 7.6 (2.7-13.6) 
Route of infection: 
- Vertical transmission 
- Others 
 
2 (100%) 
0 
 
6 (37%) 
10 (93%) 
HCV genotype: 
- 1 
- Others 
- 
 
 
10 (63%) 
6 (37%) 
Mean relative BMI±SD 132±9 112.7±15.4 
Median ALT values (IU/L (range) 133 (102-164) 117 (50-300) 
Median GGT values (IU/L 
(range) 
20 (14-26) 17 (8-79) 
Median cholesterol levels (mg/dl) 
(range) 
192 (174-210) 146 (116-201) 
Median triglycerides levels 
(mg/dl) (range) 
95 (68-123) 62 (35-99) 
Median fasting glucose levels 
(mg/dl) (range) 
85 (78-93) 72 (70-90) 
Median insulin (mU/ml) (range) - 10.15 (4.8-22) 
Median serum HBV DNA 
(copies/ml) (range) 
231494 - 
Median serum HCV RNA (IU/L) 
(range) 
- 220000 (40000-587000) 
Histology: 
- Necroinflammatory score 
- Fibrosis score 
 
4 
1 
 
4 (2-7) 
2 (1-4) 
SD= standard deviation 
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2.44 Discussion 
 
This study shows a very low frequency of liver steatosis in chronically HBV-infected 
children, while a higher prevalence was found in children with chronic hepatitis C.  
Recently, histologically proven steatosis has been found in 18% of 233 adults with chronic 
hepatitis B and it was mild in the majority of cases (4). Another study showed a percentage of 
steatosis higher (76%); however, it included patients with alcohol consumption, a well-known 
risk factors for steatohepatitis (7). The prevalence of histological evidence of hepatic steatosis 
found in our HCV-infected children is similar to that reported in adults, accounting for about 
25% (6).  
In HBV infection steatosis appears to be unrelated to virological factors. In previous studies 
on adults patients, only metabolic parameters (such as fasting glucose and overweight) were 
correlated with the presence of steatosis at liver histology while no correlation was found with 
HBV DNA titre and HBeAg status (4,7). In a double-transgenic mouse model expressing the 
HCV coding sequence and the HBV X gene-encoded regulatory protein HBx it has been 
showed that steatosis was more prevalent and severe in presence of HBx protein expression 
(19). Nevertheless, the direct steatogenic role of HBV has not yet been demonstrated. In our 
population of HBV-infected otherwise healthy children no correlation was found between 
viral factors and presence of steatosis. Hepatic steatosis was only associated with higher BMI. 
However, the number of children with chronic hepatitis B and steatosis was too small in order 
to evaluate if viral factors might play a role in determining liver steatosis.  
In adults with chronic hepatitis C, two distinct mechanisms are involved in the development 
of hepatic steatosis. In patients infected with HCV genotype 1, metabolic factors of the host, 
such as obesity and metabolic syndrome, play a major role in intracellular lipid accumulation 
while in HCV genotype 3 infected adults steatosis seems to be viral-induced (6,8,20). At 
variance with these data, our results suggest a direct association between genotypes other than 
3 and hepatic steatosis, since children with steatosis infected with genotypes non-3 had similar 
relative BMI and percentages of overweight and obese subjects with respect to patients 
without steatosis. Furthermore, according to a previous report (21), our data show that the 
degree of insulin resistance, expressed by HOMA, was not associated with hepatic steatosis. 
This observation is noteworthy in view of the debated role of HCV infection in the 
establishing of an insulin resistance state. It remains unexplained the reason why in children 
and not in adults genotypes non-3 are associated with hepatic steatosis in absence of metabolic 
causes. It would have been very interesting to explore the behaviour of hepatic steatosis in 
genotypes non-3 infected children who achieved a sustained response to IFN therapy, but for 
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ethical reasons a follow-up biopsy was not performed in these subjects. Owing to the low 
prevalence of genotype 3 in Italian children, in the present study only 3 patients were infected 
with this genotype, so the relationship between genotype 3 and steatosis was difficult to 
evaluate in this context. Therefore on the basis of the present data, we can not exclude a direct 
association between genotype 3 and steatosis.    
As for the relationship between steatosis and severity of liver damage, it has been reported 
that adults with chronic hepatitis C and steatosis show a more severe liver disease in terms of 
necroinflammation, fibrosis and aminotransferases serum levels (6). We found no relationship 
between steatosis and activity of necroinflammation in liver histology, and the median serum 
level of transaminases did not differ between children with and without steatosis. It is to note 
that in the group of children with steatosis ALT serum levels significantly correlated with 
degree of steatosis. Furthermore, children with steatosis showed a significantly more severe 
fibrosis (fibrosis score > 2). It remains to be shown to what extent steatosis itself, or steatosis 
acting synergistically with other co-factors, contributes to the severity of fibrosis.  
Analysis of treatment outcomes in children with chronic hepatitis C indicated that, although 
response to IFN was not significantly related to presence of steatosis, children with steatosis 
were less likely to achieve sustained response to therapy. This result, in agreement with 
previous studies in adults with chronic hepatitis C (9,22), suggests that steatosis might induce 
a mechanism of resistance to IFN treatment. 
In conclusion, our research shows that steatosis in children with chronic hepatitis B is a rare 
event which seems to be related to the host rather than the effect of virus. On the basis of these 
findings, we think that the detection of liver steatosis in a non-obese child with chronic 
hepatitis B can not be explained with HBV infection but must be carefully investigated to rule 
out the other multiple causes of pediatric fatty liver. In children with chronic hepatitis C 
hepatic steatosis is a frequent finding and, differently from adults, genotypes other than 3 may 
be associated with steatosis independently from the presence of classical metabolic risk 
factors.  
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CHAPTER 3 
 
 
CHILDREN WITH HIV INFECTION 
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3.1 Perception of disease and adherence to antiretroviral therapy in HIV-
infected children 
 
 
3.11 Rationale 
 
In the past two decades, the nature of pediatric HIV has radically shifted. Highly active 
antiretroviral therapy (HAART) involving multiple drug combinations have proven effective 
in controlling clinical disease progression and reducing mortality among both adults and 
children (1,2). As a result, while rates of new infections among infants have declined 
dramatically, perinatally infected children and youth are surviving longer (3,4).  
While the advent of HAART has improved survival among children and adolescents with 
HIV, the regimens are demanding and require strict adherence in order to avoid medication 
resistance and achieve lasting clinical benefits (5-7). Adherence failure may result in early 
antiretroviral therapy (ART) failure, development of resistance to ART and subsequently 
reduction of treatment options. Owing to highly dynamic viral replication in HIV infected 
patients, it is now clear that even limited omissions of doses may lead to selecting resistant 
strains and ultimately to treatment failure (7,8). Most studies indicate that adherence to ART 
is suboptimal among children and adolescents. A recent review of 13 studies revealed a 
pediatric adherence ranging from 50% to 75% (6). An array of heterogeneous conditions 
affect treatment adherence in AIDS. Studies of caregivers of children with HIV have shown 
that compromised adherence is associated with the complexity of the regimen (9-11). A small 
number of studies have examined psychological influences on pediatric adherence, 
suggesting an important link with individual and family characteristics and situations (12-14). 
Adherence among children and adolescents with HIV is affected by the quality of parent-
child communication, level of caregiver stress and quality of life, caregiver cognitive 
functioning, children‟s exposure to stressful life events and experiencing depression 
(12,13,15). In a previous cross-sectional assessment of adherence and its major determinants 
in 7 major Italian references centers for pediatric HIV-infection, we found that 21 (16%) of 
129 children with HIV infection failed to adhere to treatment (14). In addition, we found that 
psychosocial rather than demographic or clinical features were major determinants of 
adherence. Indeed, the relationship between the caregiver and the child was the strongest 
determinant of adherence with foster parents being more adherent than relatives and 
biological parents.  
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Perception of disease and of the benefits of ART may favor acceptance of changes in therapy 
schedule, and eventually promote child adherence (16). The importance of promoting and 
maintaining optimal adherence in pediatric patients is recognized in several authoritative 
documents and guidelines, and careful monitoring is recommended (17,18). In Italy, children 
with HIV infection are cared for according to the recommendations of the Center for Disease 
Control (17) and the Italian Register for HIV infection. The latter coordinates the medical 
care of children in Italy and was established at the onset of the HIV epidemic (19-21). All 
HIV-positive children have free access to medical care, including antiretroviral and non-
specific drugs, visits and procedures.  
Adherence is a dynamic phenomenon and determinants of adherence change over time. 
However, few studies have examined the dynamics of adherence to ART. Drug switching due 
to non-adherence, failure of therapy, viral resistance, toxicity or even to improvements in 
HAART can influence the quality of life, the psychological dimension and the behavior of 
HIV-infected patients (22). Little is known about the effects of switching therapy on HIV-
infected children and their caregivers and on adherence to ART.  On June 6
th
 2007, the 
European Medicines Agency (EMEA) announced the recall by the manufacturer of the 
protease inhibitor nelfinavir (Viracept, Roche) from the market because of possible 
contamination of tablets with the genotoxic substance ethyl mesylate. As a consequence, all 
patients who were receiving nelfinavir had to be switched to a different drug regimen.  
 
The first aim of this research was to investigate the effect of switching therapies on the 
perception of the benefits of ART and adherence to treatment in HIV-infected children and 
their caregivers. 
The second aim of this research was to investigate in a multicenter study the evolution of 
adherence to ART 12 months after an initial (baseline) evaluation in a population of HIV-
infected children. 
 
 
3.12 Experimental procedures 
 
Children and adolescents with HIV infection who switched ART 
To investigate the effect of switching therapies on the perception of the benefits of ART and 
adherence, HIV-infected children and their caregivers attending our Pediatric AIDS Reference 
Center were considered for enrolment. Caregivers of enrolled children completed a 
questionnaire during a face-to-face interview. The questionnaire contained information on 
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demographic data, awareness of HIV status, perception of treatment efficacy, reaction to the 
“change of therapy” event, reasons for taking, missing or discontinuing drugs, and factors 
potentially influencing adherence. The questionnaire was administered by a psychologist 
trained in HIV infection at the time of or within one month after nelfinavir recall or treatment 
shift for other reasons. In the same period, caregivers of children who did not change therapy 
were administered the same questionnaire, except for the questions related to the change of 
antiretroviral drugs. Awareness of HIV status was established based on the child‟s knowledge 
about HIV infection. Adherence was evaluated at enrolment and subsequently during the 4
th
 
month after shifting, as part of the routine follow-up for HIV-infected children (scheduled 
every 2 months).  
 
Children and adolescents with HIV infection included in the multicenter study 
To investigate the evolving pattern of adherence an observational, cross-sectional multicenter 
study was performed through a structured interview to the caregivers of HIV-infected 
children. The study was carried out in the same 7 major Italian centers for pediatric HIV-
infection as the previous study (14). The same investigator (V.G.) visited each center for one 
to two days and interviewed caregivers of children with HIV symptomatic infection who were 
scheduled to visit the center for routine follow-up visits. A face-to-face structured interview 
based on a standardized scripted dialogue was administered to persons in charge of drug 
administration (caregivers). Data on socio-demographic and clinical features of enrolled 
children, their awareness of HIV status, prescribed antiretroviral therapy and adherence to 
drug regimen were collected. Each interview lasted for approximately 20 minutes.  
 
Definition of caregiver 
 “Caregiver” was the person who routinely administered antiretroviral drugs to enrolled 
children and accompanied the child to the hospital for routine follow-up on the day of the 
interview. Caregivers were classified as biological parents, foster parents or second-degree 
relatives.  
 
Adherence assessment  
To estimate adherence quantitatively, each caregiver was asked how many doses of the total 
prescribed antiretroviral therapy had been omitted in the last 4 days. The 4-day instrument is a 
reliable surrogate marker for monthly adherence and was used in the previous study (9,23). A 
dose was defined as the intake of any pill, syrup or suspension of any antiretroviral drug in 
one day. Since adherence rates equal to or less than 95% of prescribed doses have been 
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associated with suboptimal virologic outcome, children were defined as non-adherent if they 
had taken less than 95% of all prescribed doses of antiretroviral therapy in the last 4 days. 
Threshold levels were prospectively labeled as follows: adherence (≥95% of prescribed doses 
regularly taken), low adherence (<95%, but >80% of doses taken) and poor adherence (<80% 
of doses taken). Compliance with administration time wad intended as the percentage of doses 
taken within 2 hours of a target time. 
 
Clinical and laboratory parameters 
Clinical and immuno-virological parameters (count of CD4-positive lymphocytes and plasma 
HIV RNA levels) were evaluated at the time of the administration of both questionnaires.  
At the time of the multicenter study, the lower detection limit of the viral load assay was 200 
copies of HIV RNA/ml.  
 
Statistical analysis 
Statistical analysis was performed using SPSS version 14.0 (SPSS, Chicago, IL, USA). The 
significance of the differences between the groups was assessed by the chi square test and 
Fisher‟s exact test for dichotomous variables. In case of more variables, we applied the chi 
square test for independence. Continuous variables were compared with the Student t test and 
the Mann-Whitney test. When the study groups were more than 2, the ANOVA test was used 
for continuous variables. A two-sided test was used to indicate statistical significance at a p 
value of <0.05.  
 
 
3.13 Results 
 
Effect of switching therapy on ART perception and adherence 
Thirty-eight (13 males; mean age 12.1±6.7 years) out of 45 HIV-infected children attending 
our center were enrolled in the study. One child was excluded because of a recent diagnosis of 
HIV infection. The remaining 6 children were not included because they did not attend our 
center during the study period (4 patients) or refused to participate (2 cases).  
Based on treatment history, enrolled children were divided into 3 groups: patients who were 
shifted because of nelfinavir recall (group A; 8 children, 3 males; mean age 11.2 years); 
patients who were shifted in the month before nelfinavir recall or in the following 5 months 
for other reasons (group B; 12 children, 6 males; mean age 12.6 years), i.e. emergence of viral 
resistance (7 patients), toxicity (3 patients) and non-adherence (2 patients); and patients who 
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were not shifted (group C; 18 children, 4 males; mean age 10.4 years). Demographic and HIV 
RNA related parameters did not differ significantly between the three groups except that the 
primary caregiver was more frequently a biological parent in group A than in group B 
(p=0.02) and C (p>0.05). Overall, 12 (32%) children (mean age 14.7±2.1 years) were aware of 
their HIV status and managed their own therapy. In the remaining 26 (68%) children (mean 
age 9.3±3.4 years; p<0.0001), medications were administered by the primary caregiver.  
Treatment-related feelings are reported in table 1. Most caregivers were satisfied with the 
health status of their children and all caregivers considered HAART necessary and effective, 
without significant differences between the groups. It is noteworthy that 18 (47%) caregivers 
were receiving HAART. There were a few worries with antiretroviral drugs, which were 
effectively dealt with by patients and their families. However, more caregivers of group B did 
not trust therapy (i.e., they did not believe in the efficacy of treatment) compared to groups A 
and C (p=0.03) (table 1).   
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Table 1. Perception of antiretroviral therapy and adherence to treatment in 38 HIV-
infected children 
 Group A 
(N=8) 
Group B 
(N=12) 
Group C 
(N=18) 
Total 
(N=38) 
How do you consider health status of 
your child? 
- Good 
- Poor  
 
 
6  (75%) 
2 (25%) 
 
 
10 (83%) 
2 (17%) 
 
 
16 (89%) 
2 (11%) 
 
 
32 (84%) 
6 (16%)  
Do you considered HAART necessary? 
- Yes 
- No 
 
8 (100%) 
0 
 
12 (100%) 
0 
 
18 (100%) 
0 
 
38 (100%) 
0 
Do you trust therapy?§ * 
- Yes 
- No 
 
8 (100%) 
0 
 
9 (75%) 
3 (25%) 
 
18 (100%) 
0 
 
35 (92%) 
3 (8%) 
Was it a problem to take the   therapy?§ 
- Never a problem 
- Hardly ever a problem 
- Frequent problem 
 
2 (25%) 
5 (62%) 
1 (13%) 
 
4 (33%) 
5 (42%) 
3 (25%) 
 
7 (39%) 
8 (44%) 
3 (17%) 
 
13 (34%) 
18 (47%) 
7 (19%) 
If it was a frequent problem, what was 
the reason?§ 
- Formulation of drugs  
- Schedule of therapy  
- Social context 
 
 
1 (100%) 
0 
0 
 
 
1 (33%) 
1 (33%) 
1 (34%) 
 
 
3 (100%) 
0 
0 
 
 
5 (72%) 
1 (14%) 
1 (14%) 
Did your child comply with the drug 
timing?§ 
- Sometimes 
- Often 
- Always 
 
 
3 (37%) 
2 (25%) 
3 (38%) 
 
 
5 (42%) 
3 (25%) 
4 (33%) 
 
 
2 (12%) 
8 (44%) 
8 (4%) 
 
 
10 (26%) 
13 (35%) 
15 (39%) 
N. of patients adherent to therapy (%) § 6 (75%) 8 (67%) 14 (78%) 28 (74%) 
§ For patients who were shifted (groups A and B), these questions were related to the therapy 
before the shift. For patients who did not change therapy, the questions were related to the 
current therapy. 
* More caregivers of group B did not trust therapy compared to group A and C (p=0.03).   
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Before switching, 28 (74%) patients met the criteria of adherence to therapy (≥95% of drug 
doses taken in 4 days), without significant differences between the groups (figure 1). 
Differently, adherence to the timing of medications was poor in a substantial number of cases 
but without differences between the groups. Patients adherent and not adherent to treatment 
did not differ by age (mean age 11.4±4.1 vs 10.5±4.1, respectively; p>0.05), sex (39% of 
males vs 20%, respectively; p>0.05) or race (Caucasian origin in 71% of cases vs 80%, 
respectively). Specific family factors were significantly associated with adherence rates. All 
children cared for by foster parents adhered to therapy compared to 62% of children cared for 
by biological parents (p=0.03) and 71% of children cared for by second-degree relatives 
(p>0.05). Increased adherence rates were associated with a higher education in caregivers. 
Fifty percent of caregivers of adherent patients had a schooling above 8 years vs 90% of 
caregivers of non adherent patients (p=0.05). 
Reactions to drug shifting in 20 HIV-infected children who shifted therapy are reported in 
table 2. Shift of therapy, either because of nelfinavir withdrawal or for other reasons, 
generated anxiety and concern in most caregivers, without differences between the groups. 
Two (25%) caregivers of group A were very worried about nelfinavir toxicity. However, all 
caregivers were satisfied with the information received and reported they did not need more 
information. All but one caregiver (in group A) felt confident about the efficacy of the new 
treatment. The duration of treatment before switching did not differ between group A (median 
duration 60.5 months, range 7-96) and B (16.5 months, range 1-87; p>0.05) or between 
patients adherent and patients not adherent (median duration 45 months, range 1-96, vs 9.5 
months, range 5-77; p>0.05). Adherence rates did not change significantly after switching 
therapy in groups A and B (87% and 58% of patients adherent after switching therapy in 
groups A and B, respectively; p>0.05) (figure 1). Finally, adherence rates were higher in the 
12 patients who self-managed their therapy than in the 26 patients who received drugs from a 
caregiver, although the difference was not statistically significant (percentage of adherent 
patients 83% vs 64%, respectively: p>0.05).   
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Figure 1. Percentage of patients adherent to therapy at baseline (for all groups) and 
after drug switching (for groups A and B) 
Adherence: ≥95% of prescribed doses regularly taken. 
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Table 2. Reaction to drug shifting, perception of antiviral treatment in 20 HIV-infected 
children who shifted therapy 
 Group A 
(N=8) 
Group B 
(N=12) 
Total 
(N=20) 
What was your feeling when your child 
needed to change therapy? 
- Reassurance 
- Indifference 
- Concern                                
- Anxiety 
 
 
0 
1 (12%) 
6 (75%) 
1 (13%) 
 
 
2 (17%) 
0 
9 (75%) 
1 (8%) 
 
 
2 (10%) 
1 (5%) 
15 (75%) 
2 (10%) 
Why did you feel worried? 
- Side effects 
- Drug toxicity 
- Inefficacy of the new therapy 
 
2 (29%) 
2 (29%) 
3 (42%) 
 
5 (50%) 
0 
5 (50%) 
 
7 (42%) 
2 (11%) 
8 (47%) 
Do you trust new therapy? 
- Yes 
- No 
 
7 (87.5%) 
1 (12.5%) 
 
12 (100%) 
0 
 
19 (95%) 
 1 (5%) 
If no, why? 
- Side effects 
- Long-term efficacy 
 
1 (100%) 
0 
 
- 
- 
 
1 (100%) 
0 
§ Adherence to the new treatment was evaluated during  the 4
th
 month after shifting. 
None of the analyzed variables differed statistically between the two groups.  
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Evolving pattern of adherence 
In the first study 129 HIV-infected children (median age 96 months, range 4-204) were 
enrolled in 7 major Italian reference centres for pediatric HIV infection (14). One hundred and 
eight patients (84%) were adherent to therapy. Adherence with administration times was very 
poor and only 14 (11%) caregivers reported that they were complied with. An inverse 
relationship was detected between adherence and awareness of HIV infection. When 
adherence rates were analysed according to caregivers, it was observed that adherence was 
higher in children receiving drugs from foster parents than in those receiving treatment from 
biological parents and second degree relatives (14).  
Of the 129 children enrolled in the first study, 112 (87%) patients (57 males; median age 108 
months, range 12-216; mean duration of therapy at baseline 74 months ± 37) were available to 
be checked for adherence after a mean of 12 months. The other 17 children were not included 
because they did not attend the follow-up visit or their caregivers refused to take part in the 
second survey. 
The overall adherence rate was 83% (figure 2). This included 88 (79%) children who took all 
doses and 5 who omitted one dose only in the last 4 days but were considered adherent 
according to the cut-off threshold (adherence rate >95%). Nineteen (17%) children did not 
adhere to treatment, and two of these children did not take any doses at all.  
The changes in adherence pattern were as follows: of the 19 non-adherent children, 10 (53% 
of non-adherent) were non-adherent at baseline and were therefore labelled as “persistently 
non-adherent”. Conversely, 9 children (47% of 19 non-adherent patients) were adherent at 
baseline and were defined “new non-adherent”. Exactly the same number of children shifted 
from having been non-adherent at baseline to adherent and were defined “new adherent”. A 
comparison with baseline data revealed that non-adherent children had a significant risk of 
remaining non-adherent after 12 months (RR=5.44, O.R. 10.37, C.I. 1.56 to11.55).  
Similar to our previous findings, compliance with administration times was very poor with 
only 16 (14%) caregivers reporting that they did administer doses in due time. The vast 
majority (70 of 112 caregivers, 63%) reported that adherence with prescribed times was 
limited, and 26 (23%) of caregivers reported no adherence at all with administration times.  
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Figure 2. Rates of adherence in 112 HIV-infected children according to key 
informants 
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When we examined determinants of adherence, we found no significant difference between 
adherent and non-adherent patients with respect to gender, clinical class, severe or less than 
severe immune impairment as well as number of patients with undetectable viral load (figure 
3). However, among patients with detectable HIV RNA, median viral load was significantly 
higher in non-adherent (HIV RNA median value 2870 copies/ml, range 250-100000) than in 
adherent children (HIV RNA median value 510 copies/ml, range 220-12200) (p=0.03). 
Twenty-seven children fully adherent either at baseline and after 12 months had a viral load 
below 200 copies/ml. 
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Figure 3. Rate of adherence in HIV-infected children with detectable or undetectable 
HIV RNA 
The lower detection limit of the viral load assay at the time of the study was 200 copies of 
HIV RNA/ml.  
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When we examined the correlation between adherence and ART regimens (number of doses), 
we found that children receiving more than six doses per day were more adherent than those 
receiving fewer than six doses (table 3). The cut-off of six doses per day was based on the 
median number of administrations per day in the overall population. Although the pattern of 
adherence varied widely in relation to individual drugs, no significant difference was found 
between adherent and non-adherent patients in relation to treatment type, with the exception 
of 6 patients taking lopinavir/ritonavir, who were all non-adherent (p<0.05 versus all the other 
individual drug). This result can be explained by the low palatability of lopinavir/ritonavir oral 
suspension. 
Finally, adherence was strongly related to the caregiver, being significantly higher in children 
receiving treatment from foster parents than from biological parents (table 4). A similar 
pattern emerged from the baseline analysis in the same 112 caregivers, although the difference 
was not significant (table 4). Between the first and the second study, 18 children (11 males; 
median age 14.3 years, range 13-16.5) had been instructed to self-administer antiretroviral 
drugs. Five of these 18 children (28%) were non-adherent. The difference was statistically 
significant when these children were analyzed as a single group and compared with children 
receiving treatment from foster parents (table 4).  
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Table 3. Adherence according to number of doses of antiretroviral therapy per day 
No. of 
doses/day 
At baseline After 12 months 
 
Adherent 
Non 
adherent 
p Adherent 
Non 
adherent 
p 
<6 44 (75%) 15 (25%) 
0.01 
32 (73%) 12 (27%) 
0.03 
>6 49 (92%) 4 (8%) 61 (90%) 7 (10%) 
Data are shown as n (%) 
 
 
 
 
 
 
 
Table 4. Adherence according to the type of caregiver 
Type of caregiver At baseline After 12 months 
 
Adherent 
Non 
adherent 
p Adherent 
Non 
adherent 
p 
Biological parents 61 (78%) 17 (22%) 
0.05 
49 (79%) 13 (21%) 
0.02 Foster parents 32 (93%) 2 (7%) 31 (97%) 1 (3%) 
Self-administered 0 0  13 (72%) 5 (28%) 
Data are shown as n (%) 
 84 
3.14 Discussion 
 
Maintenance children‟s medication routine in a variety of day-to-day situations is a challenge.  
Adherence support mechanisms need to go beyond reminder system and devote specific 
attention to fitting the medications into daily schedules that can include changes in routines, 
going away from home and being in a variety of social situations. The extent to which 
medication regimens can accommodate rather than interfere with social activities may be an 
important means of reinforcing and improving adherence, particularly among adolescents.    
Adherence is affected by clinical, social and behavioural factors (13,24). Shifts in ART 
regimens due to treatment failure, emergence of viral resistance or drug toxicity may impair 
adherence. The consequences of switching therapy in HIV-infected children and adolescents 
are poorly investigated for several reasons: the low number of HIV-infected children; the role 
of caregivers in drug administration; and less frequent need to change therapy compared to 
adult patients. The perception that therapy is protective or reliable is associated with higher 
levels of adherence, whereas the perception of therapy as enslaving is associated with lower 
levels of adherence in HIV-infected adults (25). A drug recall due to a possible toxic effect 
would be expected to result in impaired adherence. The nelfinavir recall, a unique event in the 
history of HAART, gave us the chance to investigate if changes of antiretroviral drugs affect 
the perception of the benefits of therapy and adherence rates. In 12 months, a total of 21 
(47%) of 45 HIV-infected children seen at our Reference Center needed to change HAART 
and 38% of them did so because of nelfinavir recall. The switch because of recall involved 
18% of the entire population of our HIV-infected children. Switching was a matter of concern 
for most caregivers and induced worries and a negative general feeling, although it did not 
affect adherence rates or result in decreased trust by HIV-infected children or their caregivers. 
In our population, drug recall was not more problematic than switching for other reasons and 
it did not affect adherence rate, perhaps because patients and their caregivers had received 
clear information about the medication and about the reasons for switching.   
Adherence to ART is a dynamic phenomenon that changes with time. Our multicenter study 
shows a fairly constant distribution of rate of adherence. Quantitatively, non adherence 
remained stable at around 20% because of an equal flux of patients from adherence to non 
adherence and vice versa. This suggests that adherence should be frequently monitored and be 
a component of follow-up of children with HIV infection. Our assessment shows that also the 
determinants of adherence change over time, albeit to a lesser extent than adherence, which 
again suggests more frequent monitoring of adherence.  
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In the present study, a high percentage of adherent patients still had a viral load >200 
copies/ml and some non adherent subjects had an undetectable viral load, which resulted in a 
fairly low agreement between HIV RNA suppression and adherence rate. This inconsistency 
may have several explanations. First, adherence is a complex phenomenon and maintaining 
the prescribed adherence to medications is a continuous challenge even in adherent families. 
The self-report of medications taking during the previous 4 days does not adequately capture 
periods of non-adherence that are intermittent or present over longer time periods or that occur 
during periods of increases stress in the family. This may represent a limitation of the study. 
However, although self-report instrument may tend to overestimate adherence, the reports of 
missed doses is a practical and reliable method if used at each routine visit. Second, in some 
fully adherent children, suboptimal suppression of viral replication may be due to drug 
resistance. Third, metabolic and pharmacokinetic pattern may change with age and other 
conditions that are specific of children (i.e. the respect to timing of dosage and food 
consumption). Finally, although there was no association between viral load and complete 
adherence to antiretroviral therapy when viral load was dichotomized (more or less than 200 
copies per ml), there was a significant trend for decreased level of serum HIV RNA in 
adherent patients compared to non-adherent subjects.  
A key aspect of adherence among HIV-infected children and youth is represented by 
caregiver/family factors (13,14). Infants and young children depend almost entirely on a 
caregiver to administer medications. Adherence to treatment is, therefore, strictly dependent 
on caregivers. Biological parents of children with HIV are often HIV-infected and non-
adherent themselves, more debilitated and depressed than foster parents. This can lead to a 
decreased attention to the maintenance of adherence in their HIV-infected children. This 
research confirms that adherence is higher in children receiving drugs from foster parents than 
in children receiving medication from biological parents (14). Better adherence in children 
living with foster parents may be due to the cultural background of foster parents, that are 
selected before adoption, and to a greater sense of responsibility in non-biological parents 
compared to biological ones (9,26).  
A new class of caregivers emerged in the multicenter study, namely children who self-manage 
therapy. This group was the least adherent. Interestingly, all 5 non-adherent patients were also 
non-adherent at the baseline study. This finding carries an alarming message, namely, children 
who are managed by non-adherent caregivers tend to be non-adherent when they manage their 
own therapy. The latter is a worrying observation in the perspective of the increasing number 
of children who will directly manage their therapy.  
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Finally the relationship between adherence and more complex regimens has important clinical 
implications. This data is consistent with other reports showing that sicker adults with chronic 
diseases taking several drugs appeared to be highly complaint with therapy (27-31). However, 
in these studies, the exact number of doses taken/day was not assessed. Although the HAART 
pill burden has decreased in recent years due to simplified regimens, contrary to what might 
be expected out results show that HIV-infected patients taking more doses are more compliant 
with therapy than patients taking less doses. Is it possible to speculate that patients with more 
complex regimens may be, or believe to be, less healthy. As a consequence, they may have an 
increased perception of disease severity and, therefore, are likely to be more adherent to 
prescribed medication.   
In conclusions, adherence is a crucial variable of treatment of AIDS in children and deserves 
early and continuous monitoring and implementation. Adherence tends to change over time 
and, more importantly, non adherence in early stages of life predicts later non adherence, 
when control of therapy may become more difficult or impossible. The caregiver, the 
relationship between patient and physician, and the perception of drug efficacy are key aspects 
to obtain and maintain adherence.  
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3.4 Psychosocial issues in children growing with HIV infection 
 
 
3.41 Rationale 
 
Children and adolescents with HIV infection have to face greater challenges to their 
psychosocial well-being than their counterparts not affected by HIV (1-4). Children living 
with HIV must deal with lack of adult influence, illness or death of a parent, poverty, 
disclosure of their own or their parents‟ HIV status to  members of their community (5,6). As 
a consequence, being a child or an adolescent with HIV implies major problems in terms of 
quality of life, school attendance and social interactions with peers. Thus, notwithstanding the 
spectacular improvement in the virological, immunological and metabolic control of the 
disease due to highly active antiretroviral therapy (HAART), a number of psychosocial 
problems may affect the health status of HIV-infected patients (5). In a recent Cochrane 
review, no rigorous studies of interventions for improving the psychosocial well-being of 
children affected by HIV and AIDS were identified (7). Current psychosocial practice is based 
on anecdotal knowledge, descriptive studies and situational analyses.  
The identification of needs is mandatory to improve the psychosocial well-being of this 
vulnerable population. Assessment of psychosocial problems in HIV is hampered by the lack 
of standard instruments to evaluate these issues in growing children and adolescents (8). The 
International Classification of Functioning, Disability and Health (ICF) of the World Health 
Organization adapted for children and young people (ICF-CY) is an age-specific descriptor 
system  devised to evaluate the health status and disabilities of a person or a group of persons 
and ideally completes the information to outweigh the global impact of a given disease (8-11). 
It encompasses information on health using a bio-psycho-social approach that takes into 
account physical health as well as the social context and other factors that may favor, or 
impair, school, work, and social achievements. Application of the ICF to pediatric HIV 
infection may provide a framework for standardizing data collection and for evaluating health 
care interventions.  
 
The aim of this study was to investigate the feasibility of applying the ICF to determine the 
health status and needs of a population of children and adolescents with HIV infection seen at 
a reference center for pediatric AIDS in Europe. 
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3.42 Experimental procedures 
 
Patients with HIV infection 
Children in follow-up at two HIV reference centers located in Southern and Northern Italy, 
namely in Naples and Brescia, were enrolled. In both institutions, the children are managed 
according to the recommendations of the Center for Disease Control (12) and the Italian 
Register for HIV infection (13-15). The latter coordinates the medical care of children in Italy 
and was established at the onset of the HIV epidemic (13-15).  
 
ICF tool 
ICF comprises a standard checklist validated at international level. The specific version for 
children and adolescents, designated ICF-CY, was devised in 2006 by the World Health 
Organization (www.who.int/classifications/icf/en/). The checklist may be completed by health 
care personnel or by other caregivers such as teachers, social workers and parents.  
The ICF encompasses 4 major areas of health and functioning of a person:  
1) impairments of body structures; 
2) impairments of body functions;  
3) environmental factors;  
4) activity limitations and restrictions to social life. 
Impairments are defined as problems in body function or structure. Information about 
impairment of body structures and functions was obtained from medical records and physical 
examination of patients. The level of impairment detected in these two areas are scored from 0 
(no problem) to 4 (complete impairment).  
The section of the ICF-CY regarding environmental factors includes a number of domains 
related to the physical, social, and attitudinal environment in which the child lives. The 
environmental factors section encompasses products and technology, natural environmental 
features and human-made changes to the environment, supports and relationships, attitudes, 
services, systems and policies that may positively or negatively affect the life of a patient. 
Environmental factors are labeled as facilitators or barriers to the development of an 
individual and are scored from 0 (no facilitator or no barrier) to 4 (complete facilitator or 
complete barrier). Activity limitations are difficulties a person may have in carrying out daily 
activities. Participation restrictions are problems a person may experience when involved in 
life or social situations. Specifically, this section encompasses 9 domains: learning and 
applying knowledge, general tasks and demands, communication, mobility, self care, domestic 
life, interpersonal interactions and relationships, major life areas, and finally community, 
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social, and civic life. This section is scored from 0 (no limitation or restriction) to 4  (complete 
limitation or restriction).For all sections, the item was classified  “code 8” (“not specified”) in 
case of insufficient information to specify the severity of the impairment, whereas the item 
was scored “code 9” (“not applicable”) if it is inappropriate to apply any other code.  
 
Data collection  
Information related to sections 1 and 2 were collected by the physicians in charge of children 
(A.G.). Data regarding sections 3 and 4 were collected by a specifically trained psychologist 
(G.G.) by means of interviews conducted in a protected setting. The key responder was the 
person responsible for the care of the child and who accompanied the child to the hospital for 
routine follow-up. Key responders were biological or foster parents or second-degree 
relatives. Each interview lasted approximately one hour. Key responders were informed about 
the objectives of the study and gave their consent to participate.  
 
Statistical analysis 
Data were analyzed with the SPSS package version 12. Considering the high number of issues 
in each section of the questionnaire, in this report we focus on the more frequent critical 
issues. Erratic issues, detected in less than 3% of the patients (1 child), are not reported herein, 
but the corresponding author will provide information on all items of the ICF checklist upon 
request. 
 
 
3.43 Results 
 
Forty-one families of HIV-infected children were enrolled, 25 from Naples and 16 from 
Brescia.  
Table 1 shows the main sociodemographic and HIV-related features of the enrolled children. 
There was a high prevalence of children of low socioeconomic status, and most of them were 
orphans. Most patients were adolescents. Overall, the major clinical, immunological and 
virological parameters of HIV infection were well controlled; viral load was low and immune 
derangement was limited.  
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 Table 1. Main sociodemographic and HIV-related features of 41 enrolled patients 
Characteristics Patients enrolled, n (%) 
Maternal education (years)*: 
≤8  
>8 
 
20 (80) 
5 (20) 
Single parent 12 (29) 
One or both parents unemployed 18 (44) 
Natural father not alive 9 (22) 
Natural mother not alive 7 (17) 
Foster families 9 (22) 
Children aware of their HIV diagnosis 13 (32) 
Age range (years) 
6-9 
10-13 
>14  
  
9 (22) 
10 (24) 
22 (54) 
Patient whose viral load was <40 copies/ml 30 (73) 
Median viral load among patients with HIV RNA 
>40 copies/ml (range) 
2935 (480-65400) 
Median CD4 (cell/mmc) (range) 923 (259-2245) 
* Information not available for some families. 
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Table 2 summarizes the main findings regarding impairments of body structures. The main 
problems reported were related to the immune system and skin, mainly due to lipodystrophy. 
The latter is considered  a “skin” problem in the questionnaire. As shown in table 3, the main 
impairments of body function concerned vision and the gastrointestinal tract.  
 
 
 
 
 
Table 2. Major impairments regarding body structures of the ICF checklist in 41 HIV-
infected children and adolescents  
 
 
 
 
 
 
* Lung tuberculosis  
** Score 2 and 3 according to CDC criteria  
*** Growth hormone deficiency 
§ Includes lipodystrophy 
 
 
Table 3. Relevant impairments regarding body functions of the ICF checklist in 41 HIV-
infected children and adolescents 
Impairments Patients with impairments, n (%) 
Eye function* 7 (17) 
Gastrointestinal function** 6 (15) 
* Myopia (5 patients), strabismus (1 patient), palpebral ptosis (1 patient) 
** Chronic hepatitis B (1 patient), chronic hepatitis C (3 patients), liver steatosis (1 patient), 
sclerosing cholangitis  (1 patient) 
  
Impairments Patients with impairments, n (%) 
Thorax* 1 (2.4) 
Immune system** 13 (32) 
Endocrine system*** 2 (5) 
Skin problems/fat distribution § 11 (27)  
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Table 4 reports the main environmental factors that were perceived to affect the quality of life 
of subjects enrolled in the study. Many environmental factors of the ICF checklist were 
considered by the key informants as barriers, whereas none was considered a facilitator. In 
addition, the barriers were scored “severe” or “complete” by more than 50% of the key 
informants interviewed. A major issue was limited availability of food and drugs. When the 
reasons for the limited availability of foods and drugs were investigated, the most frequent 
answers were poverty and unemployment. The majority (83%) of key informants considered 
care providers, and in particular social workers, as “barriers” because they received 
inadequate support from these institutions (public health services, school…). Moreover, when 
key informants were asked why they had classified other family members, friends and health 
and education care providers as “barriers”, the most frequent answer was that they had not 
told these people  about child‟s HIV status due to the fear of social stigma.  
 
 
Table 4. Environmental factors of the ICF checklist scored as barriers in 41 HIV-
infected children and adolescents 
Barriers Families reporting the barriers, n (%) 
Insufficient availability of: 
Food 
Drugs 
Daily consumption products 
Transportation facilities 
 
7 (17) 
6 (15) 
8 (19) 
5 (12) 
Inadequate support by: 
Other family members 
Relatives and friends 
Care providers (health, education or 
social) 
 
11 (27) 
22 (54) 
34 (83) 
Inadequate approach by: 
Other family members 
Relatives and friends 
Care providers (health, education or 
social) 
 
1 (2.4) 
8 (19.5) 
6 (15) 
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Table 5 shows the frequency of activity limitations and participation restrictions in the 
children enrolled in this study. Few parents reported specific limitations and restrictions, and 
the degree of severe or complete limitations and restrictions was approximately 50%.  
 
 
 
 
Table 5. Reported activity limitations and participation restriction in 41 HIV-infected 
children and adolescents  
Domains of activity limitations and 
participation restrictions 
Families reporting limitations and 
restrictions, n (%) 
Relationship with relatives and friends 4 (10) 
Learning in informal setting 5 (12) 
Learning at school 7 (17) 
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3.44 Discussion 
 
This is the first attempt to apply the ICF to children and adolescents with AIDS in order to 
obtain a functional profile of their psychosocial problems. ICF is an adjunct to the WHO 
International Classification of Disease (ICD-X) and serves to obtain information on both 
physical health status and  social well-being by investigating environmental and social factors 
that may influence the activities and the quality of life of an individual. Thus far, ICF has been 
applied in several chronic childhood conditions that are mainly characterized by physical 
disabilities (16-23). Application of this tool to children with HIV infection, a disease with a 
heavy burden of psychosocial issues, may also yield information useful for planning health 
care interventions.  
Impairments of body structures and functions were neither frequent nor severe in our patients 
and were well controlled by antiretroviral therapy. This is expected in a child in follow-up in a 
reference centre for AIDS in Europe, where a high standard of pharmacological care is 
guaranteed. It was easy to collect such information with the ICF, which may thus be a 
standard means for monitoring both the evolution of the disease and the impact of 
interventions. In contrast with the limited frequency and intensity of clinical problems, many 
barriers were reported in the psychosocial sections. Indeed, most key informants labeled the 
environmental factors in the checklist as barriers rather than facilitators to the participation in 
social activities of their children. Perceived insufficient availability of food, drugs, other 
products for personal use, as well as of transportation facilities, were considered a major 
critical issue. This was probably due to the high prevalence of poverty and unemployment in 
the families of HIV-infected children and the frequent absence of biological parents. 
A second critical issue reported by key informants was the lack of support provided by other 
family members and by care providers from the social, education and health sectors. The ICF 
checklist does not investigate the reasons for this lack of support, but several parents reported 
that they had not disclosed the health status of their children to family members or to other 
care providers. It is thus conceivable that, in several cases, support had not been provided 
because people who were in the position to provide (e.g. school teachers or primary care 
pediatricians) were unaware of the clinical status of the child. The reasons for not disclosing 
HIV status are probably the stigma and the fear of social exclusion associated with AIDS. 
Most caregivers did not seem confident that the social, education, and health institutions could 
take initiatives to effectively fulfill the needs of their child. However, almost all parents 
reported that their child had good social relationships and attended school regularly. Finally, it 
is noteworthy  that most adolescents enrolled in the study had not received any information 
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about their disease. Often the key informants themselves denied their consent to disclosure of 
HIV diagnosis.  
In conclusion, the ICF provides a common language for assessing the functional status of 
children and adolescents that can enhance communication between health care workers in 
charge of children with HIV. The scenario that emerges from this study is that the quality of 
life of HIV-infected children and adolescents is associated with poor psychosocial conditions 
rather than with the impairment of physical health. ICF is an easy to apply instrument to 
investigate the clinical and psychosocial status of children and adolescents with HIV infection 
and to plan interventions aimed at achieving an at least reasonable level of social participation 
by HIV-infected children and their families. The improvement of the psychosocial condition 
of HIV-infected patients should proceed in parallel with the spectacular progresses that have 
been made in the clinical, immunologic and virologic control of the HIV infection. 
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CHAPTER 4 
 
 
STRATEGIES TO IMPROVE VACCINATION RATES IN 
CHILDREN WITH CHRONIC MEDICAL CONDITIONS 
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4.1 Pneumococcal and influenza vaccination rates in children with chronic 
medical conditions 
 
 
4.11 Rationale 
 
Among vaccine preventable diseases, two are of outstanding importance and provide an 
interesting area of evaluation: pneumococcus and influenza infections. The first is a relatively 
common and potentially severe infection for which vaccines are widely available, effective 
and relatively widespread. Influenza has peculiar features related to variable degree and the 
need of annual vaccination. 
Subjects with chronic medical conditions are at increased risk for severe complications related 
to vaccine-preventable infections and should be extensively immunized for both infections 
(1,15). Influenza is associated with increased morbidity, hospitalisation and mortality in 
children with chronic medical conditions compared to healthy children (3,20,22). Similarly, 
the incidence of invasive Streptococcus pneumoniae infection in children with sickle cell 
disease, asplenia or human immunodeficiency virus (HIV) infection are 20- to 100-fold higher 
than those of healthy children during the first 5 years of life (5,18,24).    
Chronic diseases at risk of complications and hospitalisation due to influenza and/or 
pneumococcal infections include chronic cardiopulmonary disorders (such as cystic fibrosis 
and chronic cardiac diseases), chronic metabolic diseases (including diabetes mellitus), renal 
dysfunction, hemoglobinopathies and immunosuppression (including HIV infection) (1,15). 
Criteria for influenza immunization in USA by Advisory Committee for Immunization 
Practice (ACIP) now include all children aged 6 months to 18 years (14).  In Italy, influenza 
vaccination is not routinely offered to healthy children, whereas it is recommended and 
offered without costs to children with chronic conditions. The same is true for pneumococcal 
vaccination (25).   
Despite long-standing recommendations to provide pneumococcal and annual influenza 
vaccinations to children with chronic medical conditions, immunization rates in these 
vulnerable populations are poor (16). A cluster survey performed by means of interviews 
carried out at the subjects‟ home, showed less than 10% coverage for influenza and 
pneumococcal vaccinations in most primary care settings in Italy (17). A more recent a study 
evaluating influenza vaccination in Italian children with chronic disease at high risk of 
influenza complications confirmed a low rate of vaccination (11).  
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Several factors hamper implementation of these vaccinations, including problems in 
identifying at risk children and limited awareness of specific recommendations (4,7). 
Vaccination of at-risk children is largely a matter of organisation. In Italy, as well as in many 
other western Countries, children with chronic conditions are generally seen at specific 
Reference Centres, often located in Universities or major Children‟s Hospitals. However, 
children with chronic diseases are seen also by primary care pediatricians (or family 
pediatricians), like all children in the Italian Health Service. Moreover, vaccination centres 
provide vaccinations to both healthy and at-risk children. Therefore, there are multiple 
services through which a child with a chronic disease can receive immunization.  
 
The aims of this research were to investigate the rates of pneumococcal and influenza 
vaccinations in selected groups of high risk children and to comparatively define the correlates 
of missed vaccination in different diseases. Influenza and pneumococcal vaccinations were 
selected because of the different features of infections and models of immunization. 
 
 
4.12 Experimental procedures 
 
Study setting and populations enrolled 
The study was conducted between January and June 2008. Children aged 2-18 years with the 
following conditions were included: HIV infection (HIV), cystic fibrosis (CF), type I diabetes 
mellitus (DM) and children who received liver transplantation (LTx). Children <2 years and 
those diagnosed as having any of the selected chronic conditions since less than 1 year were 
excluded, in order to evaluate the rates for influenza vaccination in two subsequent seasons. 
Physicians involved in the management of children with chronic diseases, including 
pediatricians of the Reference Centres and primary care pediatricians, were enrolled and 
received a specific questionnaire. Parents or legal guardians of children received a specific 
questionnaire providing that informed consent had been given.  
 
Data sources 
Patients with chronic medical conditions were identified through the Regional Reference 
Centres for each disease. The Reference Centres for HIV infection, for CF and for LTx 
(University of Naples “Federico II”) and all three Reference Centres for DM located in 
Campania Region (University of Naples “Federico II”, Second University of Naples and “San 
Sebastiano” Hospital of Caserta) took part into the study.  
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Key instrument  
A questionnaire was administered face-to-face to caregivers of subjects aged between 2 and 
18 years with high risk medical conditions during their routine clinical evaluation at the 
Reference Centre. Parental report of vaccination status has been previously validated and has 
a reasonable sensitivity, specificity and reliability (26,28).
 
In addition to the basic questions of 
having received vaccinations against pneumococcus and influenza, the questionnaire included 
a demographic section with age, sex and age at diagnosis. Twelve items on Streptococcus 
pneumoniae infection and 13 on influenza were included to investigate caregivers' awareness 
about infection, their children's vaccination status and factors that might have affected 
vaccination status. The latter consisted of the following items: (1) who recommended 
immunization; (2) who administered the vaccines and (3) the reasons for receiving or missing 
vaccination. Children were considered immunized against pneumococcus if they have 
received heptavalent pneumococcal conjugate vaccine or pneumococcal polysaccharide 
vaccine, according to their age. Inactivated influenza vaccine is the only vaccine available in 
Italy.  
In addition, a specific questionnaire on pneumococcal and influenza diseases was delivered to 
a representative sample of 113 primary care pediatricians, corresponding to approximately 
15% of the total number of primary care pediatricians of Campania Region (southern Italy). 
Items included the specific risks of pneumococcal and influenza infections in children with 
chronic medical conditions, knowledge of current national recommendations on vaccination 
and the number of patients with high risk conditions routinely seen at their practice. Finally, 
physicians of Reference Centres were interviewed in order to investigate whether they 
routinely recommend pneumococcal and influenza vaccinations to at-risk children. 
  
Statistical analysis 
Data are expressed as medians and ranges or means and standard deviations (SD). The chi 
square and the t tests for independent samples were used to compare categorical and 
continuous variables, respectively. The Mann-Whitney test was used to compare non 
parametric data. A p value <0.05 was considered statistically significant.  
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4.13 Results 
 
Pneumococcal and influenza vaccination rates 
The questionnaire was administered to 343 caregivers of high risk children (174 males; 
median age 13 years, range 2-18) including 40 patients with HIV, 39 with CF, 59 with LTx 
and 205 with DM.  
The demographic features were similar in all 4 groups (table 1).  
 
 
 
Table 1. Demographic features of 343 at-risk children  
Patients HIV  CF LTx DM 
Number 40 39 59 205 
Males 17 (43%) 18 (46%) 34 (58%) 105 (51%) 
Median age in years 
(range) 
11 (2-18) 11 (2-18) 9.5 (2-18) 13 (2-18) 
Median age at diagnosis in 
years (range) 
3 (1-12) 0.3 (0.1-15) 0.1 (0.1-13) 8 (2-16) 
HIV=human immunodeficiency virus infection  
CF=cystic fibrosis 
DM=type I diabetes mellitus  
LTx=liver transplantation 
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Vaccination rates against pneumococcus were low and largely below 50% in all high risk 
categories, the lowest being in subjects with DM (figure 1). Vaccinated and not vaccinated 
children did not differ by sex (17/29 males versus 155/314, respectively; p>0.05) or mean 
duration of chronic disease (6.34.41 versus 75 years; p>0.05). However, children who 
received vaccine were younger than those who did not (mean age 8.24.3 versus 12.54 
years, respectively; p<0.0001).  
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Figure 1. Pneumococcal vaccination rates in 343 high risk children 
Inset: percentage of patients with DM vaccinated for pneumococcus seen at each of the three 
Reference Centres. 
DM vs HIV: p=0.0007; DM vs CF: p=0.02; DM vs LTx: p=0.002. 
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In 2006-2007, a total of 208 (61%) of the 343 children with chronic disease conditions were 
vaccinated for influenza and 135 (39%) were not. A very similar pattern was observed in the 
same population in 2007-2008 (figure 2). Similarly to findings for pneumococcus, 
vaccination rate for influenza was significantly lower in patients with DM compared with HIV 
(p=0.01), CF (p<0.0001) and LTx (p=0.0006). Vaccination rates in children seen in the 3 
Reference Centres for DM were broad ranging from 21% to 61% (figure 2). Vaccinated 
children were younger than not vaccinated (mean age 114.2 versus 124.2 years, 
respectively; p=0.03), but the mean duration of the chronic conditions was significantly higher 
in vaccinated subjects (7.84.9 years) than in non vaccinated subjects (6.55 years; p=0.001). 
This apparently surprising result is explained by the lower age at diagnosis of children with 
HIV, CF and LTx compared to DM.   
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Figure 2. Influenza vaccination rates in 343 high risk children 
Influenza vaccination rates in two subsequent winters. Inset: percentage of patients with DM 
vaccinated for influenza seen at each of the three Reference Centres. 
*p<0.05. 
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Role of physicians working in different settings in recommending vaccinations  
To investigate the role in  promoting immunization by the physicians working in specific 
Reference Centres, key responders were asked to report who recommended vaccinations. As 
shown in figure 3, physicians of the Reference Centres for HIV and LTx actively 
recommended immunization against pneumococcus, while this was not so in the 3 centres for 
DM. A similar number of physicians of the Reference Centres and primary care pediatricians 
recommended pneumococcal vaccination for CF patients. Again, the Reference Centre had a 
major role in recommending influenza vaccination to children with HIV, CF and LTx, 
whereas primary care pediatricians had a main role in case of children with DM (figure 4). 
This data may be due to the different management of these chronic conditions: children with 
HIV and LTx were rarely seen by primary care pediatricians, while for children with DM the 
pattern was more scattered and depended on the individual Reference Centre. 
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Figure 3. Reasons for receiving pneumococcal vaccination in 343 high-risk children  
Role of the Reference Centre in recommending vaccination in HIV vs CF and DM: p<0.05. 
Role of the Reference Centre in recommending vaccination in LTx vs CF and DM: p<0.05. 
“Others” includes vaccination because of previous serious influenza illness, 
recommendation by relatives or friends, information garnered from the mass media or not 
specified reason. 
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Figure 4. Reasons for receiving influenza vaccination in 343 high risk children  
** DM versus HIV, CF and LTx: p<0.0001. 
“Others” includes vaccination because of previous serious influenza illness, recommendation 
by relatives or friends, information garnered from the mass media or not specified reason. 
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Reasons for missing vaccinations 
There was a wide spectrum of reasons why patients were not vaccinated for pneumococcus 
and influenza, ranging from lack of information to parental “ideological” attitudes and 
concern. Lack of information prevailed in all groups, particularly as regards pneumococcal 
vaccination (figure 5, A and B).  
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Figure 5. Reasons for not having pneumococcal or influenza vaccinations in 343 high 
risk children   
A. Reasons for not having pneumococcal vaccination.  
B. Reasons for not having influenza vaccination.  
“Others” includes child barriers (“child was sick”), parents barriers (“no time”, “forgot”), 
system barriers (“no vaccine available”), vaccination considered unnecessary by physician or 
not specified reason. 
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Key informants were specifically asked whether they would consider pneumococcus and 
influenza infections as potentially serious diseases in their children. As a control question, we 
also asked whether they would consider these infections a severe problem in healthy children. 
Overall, a small number of parents (79/343, 23%) were aware of pneumococcus infection and 
this was perceived as a potentially severe infection by only 15% of the key informants of at-
risk children. Influenza was perceived as a serious infection by 53 (15%) caregivers, but as 
many as 243 (71%) considered it a severe disease in children with chronic medical conditions. 
A greater proportion of caregivers of CF (36 of 39, 92%) and LTx patients (50 of 59, 85%) 
were concerned about influenza infection than caregivers of HIV (25 of 40, 62%; p=0.002 and 
p=0.01, respectively) and DM children (134 of 205, 65%; p=0.0005 and p=0.003, 
respectively).  
Awareness of the severity of pneumococcus and influenza infections, as reported by key 
informants, was then correlated with vaccination rates. Significantly more children of key 
informants who were aware that pneumococcus infection could be severe, were vaccinated 
than children of key informants who did not considered pneumococcus infection as severe 
(12% versus 32%; p<0.0001). No relationship between infection awareness and vaccination 
rate was found for influenza. 
 
Reported knowledge of health care providers about national vaccine recommendations 
Physicians working in 5 of 6 the Reference Centres reported that they actively recommended 
immunization against pneumococcal and influenza to high risk children as part of their routine 
approach to children with chronic conditions. Physicians working within the same Reference 
Centre had a similar vaccination policy. In one of the 3 Reference Centres for DM, 
pediatricians advised influenza vaccination only to patients with poor metabolic control, 
whereas vaccination was considered unnecessary and not recommended in other children with 
DM. Interestingly, only 20 (25%) of the 80 children with DM followed at that Centre had 
been immunised, thus supporting the role of Reference Centre in promoting or not 
immunization. 
A total of 113 primary care pediatricians were interviewed. They reported that the proportion 
of at-risk children in the age range of 0-14 years followed at their practices was approximately 
10% of all children in their practice. The estimate included children with any chronic 
condition that would require pneumococcal and/or influenza vaccinations. 
Most interviewed pediatricians were aware of the relevance of pneumococcal (102/113, 90%) 
and influenza (109/113, 96%) infections in children with chronic medical conditions and 
reported they  recommend these vaccinations to at-risk children. When asked to indicate 
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which high risk conditions required pneumococcal and influenza vaccinations according to the 
National Vaccine Programme, the majority of them correctly identified the main categories.  
 
 
4.14 Discussion 
 
Vaccination against influenza of healthy children aged 6 months-18 years is recommended in 
the USA (14) but not in Italy (25). However, vaccination of children with chronic medical 
conditions against a wide spectrum of infectious diseases has been included in the Essential 
Levels of Care and is provided free of charge (25).
 
 
Although it is well known that pneumococcal infection can be more severe than influenza and 
that pneumococcal vaccine is protective for a long time, the vaccination rate against 
pneumococcus was low in all studied groups and far lower than influenza. This rate was 
consistent with the findings of a previous Italian study (17).
  
Data from the United States 
showed that coverage rate for pneumococcal polysaccharide vaccine in 2003 was only 37% 
among persons 18-64 year of age at increased risk for pneumococcal diseases (6). As for 
pediatric age, recent data reported an estimated coverage rate for pneumococcal conjugate 
vaccines of 31, 38 and 49% among children born in 2000, 2001 and 2002, respectively (21).  
These low rates of pneumococcal vaccination may be due to lack of knowledge by care 
providers or to low priority by public health authorities. 
Furthermore, “once in the life” administration instead of annual administration (as required by 
influenza vaccine) could reduce the opportunities that physicians have to check vaccination 
status. In our study vaccinated children were younger than non vaccinated. This result may be 
due to the Italian vaccination program that promotes pneumococcal vaccination in children 
aged less that 5 years, while no clear indications are provided for children aged 5 to 18 years 
(25).  
Approximately 60% of children with the selected chronic conditions were vaccinated against 
influenza. This rate was stable over two subsequent seasons. Recently, in a large retrospective 
observational study, a poor influenza vaccination coverage has been reported in adolescents 
with high risk conditions, with 85% of subjects who were not vaccinated in 2002 (19).
 
Immunization rate against influenza found in our study was higher than in other subjects with 
other chronic conditions (2,8,23,27) and than that reported in a previous study in Italian at-risk 
children (17).  
A suboptimal vaccination rate in at-risk children may be in part related to a lack of 
information, fear of side effects of vaccination in children who are already ill, to 
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organisational problems and difficulties to identify at-risk subjects. Furthermore, from our 
study it appears that another potential reason of the low coverage rates could be the lack of 
awareness of the severity of pneumococcal and influenza infections in at risk children, as 
reported by key informants of patients with HIV and DM.  
Immunization rates against pneumococcus and influenza were closely related to the 
underlying condition, with the lowest rate for both vaccinations occurring in patients with 
DM. This may be due to the lack of awareness of the risks related with pneumococcus and 
influenza infections by physicians in charge of children with DM. There was a clear 
relationship between immunization rates and the policy of the Reference Centres as appeared 
by the comparative evaluation of rates in the 3 Reference Centres for DM.   
According to the responses by parents and physicians, Reference Centres rather than primary 
care pediatricians were more instrumental in increasing the rate of influenza vaccination in 
patients with HIV, CF and LTx. In contrast, primary care pediatricians had a major role in 
children with DM.  
The low vaccination coverage in at-risk children largely depends from on having three 
categories of physicians, namely disease specialists, primary care physicians and vaccination 
service physicians, equally encharged with vaccination, with no clear distinction between 
them. 
It was previously found that one of the most important factors positively associated with 
vaccination was recommendation by a health care provider (9,11,13). However, it has been 
reported that health care workers‟ knowledge about recommendations on vaccinations is 
limited (11,12), and, in a previous study on the determinants of influenza vaccination, the 
majority of parents of infants stated they received information through mass media rather than 
from physicians (10).  
In summary, 3 major findings emerge from this study. Firstly, although both pneumococcal 
and influenza vaccines in Italy are provided free of charge, the immunization rate for 
pneumococcal infection is very low, whereas the immunization rate for influenza is relatively 
high, with a pattern consistent over time. Secondly, for most chronic conditions, vaccination is 
performed upon the advice of a Reference Centre. Third, the main reason of unvaccination 
was the lack of knowledge by parents of the benefits of pneumococcal and influenza 
vaccinations in children with chronic underlying diseases.  
In conclusion, immunization should be considered part of the global care of children with 
chronic medical conditions. Immunization includes three different actions: to recommend 
vaccination, to administer vaccine, to check vaccination status. For diseases principally 
managed by Reference Centres (such as HIV, CF and LTx), physicians of the Reference 
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Centres should also take the responsibility to administer vaccines. For diseases with a has a 
less defined management, more detailed information on vaccination should be provided to 
families by primary care pediatricians. To achieve optimal immunization rates in at-risk 
groups a complex array of responsibilities and functions is required. A special effort is 
required to implement pneumococcal immunization among Italian high risk children.   
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4.4 Influenza and pneumococcal vaccinations in HIV-infected children: 
assessment of methological quality of current recommendations 
 
 
4.41 Rationale 
 
Pediatric human immunodeficiency virus (HIV) infection has evolved from a rapidly 
progressive, fatal disease to a chronic infection with prolonged survival thanks to the advent of 
highly active antiretroviral therapy (HAART). However, HIV-infected subjects are at increased 
risk of severe complications related to vaccine-preventable infections (1). Prevention is 
therefore an important area of HIV care. Among the factors that must be considered when 
contemplating vaccination of HIV-infected patients are the safety, immunogenicity and 
efficacy of a given vaccine. Selected vaccines may be administered to all HIV-infected 
children. Individuals with HIV infection, like healthy children, should receive DTP, Hib, HBV 
vaccines (1). Other vaccines are more appropriate in selected patients with HIV infection. For 
example, live virus vaccines, such as measles and varicella, should be administered only to 
HIV-infected patients that are not severely immunosuppressed (CD4+ cells greater than 15%) 
(2).  
Specific features distinguish influence from other vaccine-preventable diseases: it is a frequent 
(almost inevitable) disease and it is an annual risk so that vaccination must be repeated every 
year. HIV-infected naïve patients have an approximately 10-fold higher influenza-attributable 
mortality rate than the general population (3). Even in patients on HAART, hospitalization 
rates during the influenza season are higher than in the general population and similar to that of 
at-risk groups of patients (4). The increased risk is not limited to influenza. There is evidence 
that the incidence of invasive Streptococcus pneumoniae infection in children with HIV 
infection is 20- to 100-fold higher than in healthy children during the first 5 years of life (5,6).  
The increased influenza- and pneumococcal-related diseases in HIV-infected individuals 
prompted the recommendation that HIV-infected patients be considered a high-risk group and 
a specific target for annual influenza and pneumococcal vaccinations (7-9). The past 10 years 
have seen a plethora of guidelines, consensus statements and systematic reviews on preventive 
aspects of HIV-infected children. However, the increase in the number of guidelines and 
recommendations has been accompanied by growing concern about their quality (10-16).  
 
The aim of this study was to identify and assess the quality of guidelines and of consensus 
statements concerning influenza and pneumococcal vaccinations in HIV-infected children. To 
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indirectly evaluate the reliability and quality of the studies on which the recommendations 
were based, we also analyzed systematic reviews for rigor and production methodology. Rather 
than focusing on their content, our primary objective was to review the methods applied in 
writing the recommendations and to identify the fields of major weaknesses.  
 
  
4.42 Experimental procedures 
 
Search strategy 
The following definitions were applied in this study. A guideline is a systematically developed 
statement to assist practitioners make decisions about appropriate care for specific diseases 
based on evidence (17,18). Consensus statements are documents representing the opinion of a 
panel of experts to help clinicians the most agreed-upon approach to clinical practice. A 
systematic review is a methodologically rigorous process with which to analyze and 
summarize scientific evidence (19). The development of a systematic review is based on a 
“step by step” process that includes formulation of review questions, definition of 
inclusion/exclusion criteria, detailed search strategy and a critical appraisal of the studies 
selected through specific quality scales and checklists (19).  
We screened PubMed and Embase for guidelines, consensus statements and systematic reviews 
on influenza and pneumococcal vaccinations in HIV-infected patients. The following search 
terms were used: influenza vaccines, pneumococcal vaccines and HIV infection. The keywords 
used for the search strategy in Medline were: (“HIV infections”[Mesh] AND “Influenza 
Vaccines” [Mesh] AND “Guidelines” OR “Systematic review” [Mesh]); (“HIV 
infections”[Mesh] AND “Pneumococcal Vaccines” [Mesh] AND “Guidelines” OR 
“Systematic review” [Mesh]). For papers identified within PubMed, we applied the definition 
of guideline and systematic review based on the Mesh term that identified them in the 
database. To be more specific, if a paper was identified in PubMed with guidelines in Mesh, it 
was labeled as such. Inclusion criteria were: studies in English; published in the last ten years. 
We also explored relevant websites of agencies involved with HIV infection, vaccinations or 
guidelines such as AIDSinfo (http://www.aidsinfo.nih.gov/); American Academy of Pediatrics 
(AAP, www.aap.org); Centers for Disease Control and Prevention (CDC, www.cdc.gov); 
National Guideline Clearinghouse (NGC, www.guidelines.gov); Cochrane Database of 
Systematic Review (www.cochrane.org); Scottish Intercollegiate Guidelines (SIGN, 
www.sign.ac.uk); Canadian Medical Association (CMA, www.cma.ca). Where one review was 
an update of a previous review, only the most recent publication was considered. To identify 
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additional relevant studies, we also searched the reference lists of published guidelines, 
protocols and systematic reviews. 
 
Selection criteria 
Articles were selected in a two-step procedure. First, two investigators (AG and ALV) 
independently screened all titles and abstracts concerning influenza and pneumococcal 
vaccinations in HIV-infected patients potentially relevant for the present study. Studies 
meeting inclusion criteria were fully read. Three issues on influenza and pneumococcal 
vaccinations were considered: recommendations for vaccination, and the efficacy and safety of 
vaccines. 
 
Instruments to assess quality 
We evaluated the scientific quality the selected guidelines using the Appraisal of Guidelines 
for Research and Evaluation (AGREE) instrument, which is an internationally validated 
instrument for assessment of the quality of the reporting and of some aspects of 
recommendations (20). AGREE provides an assessment of the predictive validity of a 
guideline. It provides a framework with 6 domains and a total of 23 items for the assessment of 
several components that are integral to guideline development: “Scope and Purpose” (3 items), 
“Stakeholder Involvement” (4 items), “Rigor of Development” (7 items), “Clarity and 
Presentation” (4 items), “Applicability” (3 items), “Editorial Independence” (2 items). Each 
item is scored with a 4-point scale ranging from „strongly disagree‟(1) to „strongly agree‟ (4). 
The score for each domain is obtained by summing all the scores of the individual item in a 
domain and is expressed as percentage of the maximum possible score for that domain. 
Although a threshold to label a domain “good” or “bad” has not been established, a domain 
scoring less than 50% is considered not appropriate. The final step of AGREE is a judgment of 
a guideline application as “strongly recommended”, “recommended (with provisos)”, “would 
not recommend” or “unsure”.  
Four independent investigators (AG, ALV, AF and VG) extracted data and evaluated the 
scientific quality of guidelines. Reviewers also determined whether the guideline was 
evidence-based or consensus-based. The AGREE instrument was also used to evaluate the 
quality of consensus statements, as previously reported (13). Consensus statements may have a 
less rigorous development process than guidelines; consequently, a lower score should be 
expected. Agreement between reviewers on the scores given to each item of the AGREE 
instrument was also evaluated.  
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The quality of systematic reviews was assessed with methodological checklists produced by 
the Scottish Intercollegiate Guidelines Network for the evaluation of effectiveness of health 
assistance (21). This instrument includes the following methodological items: “the study 
addresses an appropriate and clearly focused question”; “a description of the methodology used 
is included”; “the literature search is sufficiently rigorous to identify all the relevant studies”; 
“study quality is assessed and taken into account”; “there are enough similarities between the 
studies selected to make combining them reasonable”; “what types of study are included in the 
review?”. A six-point scale (from “well covered” to “adequately addressed”, “poorly 
addressed”, “not addressed”, “not reported” and “not applicable”) was used to evaluate the 
validity of each item. A final question (“how was the scientific quality rate of the overview?”), 
based on the previous items, and expressed by a score ranking from – to ++ (indicating 
superior quality) was used to assess the overall scientific quality of the systematic review. 
 
Statistical analysis 
Dichotomous variables were analyzed by the chi square test and Fisher‟s exact test. 
Continuous variables were compared with the Student t test and the Mann-Whitney test. A 
two-sided test was used to indicate statistical significance at a p value of <0.05. To measure 
the agreement between reviewers, we used the Free-marginal multirater kappa (multirater 
kfree). We choose this statistical instrument because it was appropriate for the typical 
agreement study (22). Fleiss‟ multirater kappa, generally used to assess agreement between 
more than two raters, is influenced by prevalence and bias, which can lead to the paradox of 
high agreement but low kappa. The response categories were dichotomized into strongly 
agree/agree versus disagree/strongly disagree because this analysis of agreement was 
considered sufficient at this level to estimate consistency of rating between evaluators. The 
measure reflects the degree of agreement in classification over that expected by chance and 
ranges between 0 and 1.The k statistic was then applied to each of the 23 items of the AGREE 
instrument.  
 
 
4.43 Results 
 
The search in Pubmed and Embase yielded 22 citations that met the inclusion criteria (12 
citations on influenza and 10 citations on pneumococcus vaccinations). Eight additional 
citations were identified in the websites. After screening titles and abstracts and removing 
duplicates, 19 (63%) of the 30 citations were considered relevant. Based on full text reading, 
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18 met the selection criteria (1,2,8,9,23-36). One article was excluded because it did not 
contain recommendations (37).  
Nine of the 18 selected articles were guidelines or consensus statements, and 9 were systematic 
reviews.  
 
Quality assessment of guidelines and consensus statements  
Five guidelines and 4 consensus statements were analysed and the AGREE scores are reported 
in table 1.  
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Table 1. Quality assessment of recommendations of influenza and pneumococcal vaccinations in HIV-infected children 
Study  
[type of article]* 
Domain scores (%) 
Mean score (%) Scope/ 
purpose 
Stakeholder 
involvement 
Rigor of 
development 
Clarity and 
presentation 
Applicability Editorial 
independence 
Kaplan JE [G] (2) 83.3 58.3 56 81.3 30.6 16.7 54.4 
Fiore AE [G] (8) 52.8 33.3 52.4 70.8 30.6 8.3 41.4 
NACI [CS] (9) 52.8 31.3 33.3 58.3 25 20.8 36.9 
Overturf GD [CS] (31) 75 29 38.1 46 28 17 38.8 
AAP [CS] (32) 78 23 38.1 77 28 8.3 42.1 
NY State Dept. of 
Health 2003 [G] (33) 
 
38.9 
 
33.3 
 
19 
 
35.4 
 
11.1 
 
25 
 
27.2 
Geretti [G] (34) 52.8 27.1 27.4 72.9 19.4 16.7 36.0 
ECDC [CS] (35) 72.2 22.9 19 43.8 0 8.3 27.7 
NY 2006 [G] (36) 30.6 22.9 26.2 48.3 16.7 45.8 31.7 
Mean score 59.6 31.2 34.4 59.3 21.0 18.5  
G=guideline 
CS=consensus statement 
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The overall mean score ranged from 27.2% to 54.4%. One guideline scored ≥50% of the 
AGREE criteria thereby meeting the standard of good overall quality (2). Interestingly, 
consensus statements had a total score comparable to that of guidelines (mean scores 54% vs 
53%, respectively; p=0.7).  
The domain “Scope and Purpose”, which evaluates the aims of a guideline, the specific clinical 
questions and the target patient population, had the highest mean score. Seven (78%) of 9 
analyzed papers performed well in this domain scoring ≥50%. Similarly, the “Clarity and 
Presentation” domain, which deals with the language and format of the guideline, had a good 
total score, and the score was ≥50% in 5 (55.6%) cases. Lower scores were obtained for the 
“Stakeholder Involvement” domain, which evaluates the degree of a guidelines to represent the 
views of its target users, for “Applicability”, pertaining to the organizational, behavioral and 
cost implications of applying the guideline, and for “Editorial Independence”, which addresses 
the independence of the recommendations and disclosure of possible conflict of interest. The 
score for these domains was lower than 50% in all papers but one. The “Rigor of 
Development” domain had a low mean score with only two (22.2%) guidelines scoring more 
than 50%. This domain deals with the process used to search for evidence and criteria for 
selecting them, the methods to formulate the recommendations, the link between the 
recommendations and the supporting evidence, consideration of health benefits, side effects 
and risks, external revisions of the guideline and procedures to update it. Low scores were 
largely due to poor reporting. Specifically, two (22.2%) guidelines described methods for 
searching and selecting the evidence, only one (11.1%) described the methods used to 
formulate the recommendation and another (11.1%) was externally reviewed. The strongest 
item of this domain was that on health benefits, side effects and risks when formulating the 
recommendation, which was well described in 7 (77.7%) cases. 
Of the 9 guidelines and consensus statements evaluated, 3 (33.3%) were evidence-based. The 
AGREE score tended to be higher for evidence-based guidelines than for non evidence-based 
recommendations (mean score 44.2% vs 35.1%, respectively; p=0.1), but the difference was 
significant only for the “Clarity and Presentation” domain (mean score 77.1% for evidence-
based recommendations vs 50.4% for non evidence-based recommendations; p=0.009). 
After completing the AGREE instrument, the appraisers came to a consensus with respect to an 
overall recommendation for each guideline. A guideline was recommended (“strongly 
recommended” or “recommended with provisos”) if it had a fairly good quality with the 
AGREE and was considered useful to health-care providers. Overall, the reviewers 
recommended 5 (2,8,31,32,34) of the 9 guidelines (55.6%) for use in local practice.  
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Agreement among reviewers 
The agreement among reviewers for the 23 items of the AGREE Instrument is reported in table 
2. Agreement was higher than 60% for most items. Only 5 (22%) items had an agreement score 
less than 50%. Agreement was not fair (<40%) or poor (<20%) for any of the 23 items. The 
percentage of agreement among reviewers was lowest for the “Applicability” domain (for all 
the items of this domain, agreement was less than 60%); agreement was highest for the 
“Clarity and Presentation” domain (>60% for all items).  
 
 
 
Table 2. Agreement among reviewers for AGREE Instrument 
Agreement, % N. of items 
(agreement calculated by Fleiss test) 
0-20 0 
21-40 0 
41-60 11 (48%) 
61-80 12 (52%) 
>81 0 
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Quality assessment of systematic reviews  
The quality score of the systematic reviews analyzed is reported in table 3. The question 
addressed by the study was sufficiently clear in 6 (66.7%) of 9 reviews. The methodological 
quality areas had the lowest scores. In four reviews search strategies were not reported. 
Overall, only 3 (33%) reviews fulfilled all or most quality criteria, and 2 (22%) fulfilled some 
criteria. 
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Table 3. Quality assessment of systematic reviews on influenza and pneumococcal vaccinations in HIV-infected children 
Author  Scope and 
purpose 
Search 
methods stated 
Search 
comprehensive 
Study quality 
assessment 
Combine 
findings 
Overall 
scientific 
quality 
Overton ET (1) C NA NA NA NA - 
Anema A (23) B A A B B ++ 
Zanetti AR (24) C NA NA NA NA - 
Neuzil KM (25) B NA NA NA NA - 
Brydak LB (26) A B B NA NA + 
Destefano F (27) B A A B B ++ 
Bliss SJ (28) B A C B A ++ 
Spencer DC (29) C NA NA NA NA - 
Pai VB (30) B B C B NA + 
A=well covered; B=adequately addressed; C=poorly addressed, NA=not addressed. 
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Analysis of the content of recommendations 
All guidelines, consensus statements and systematic reviews recommended influenza and 
pneumococcus vaccinations for HIV-infected children. Two systematic reviews on 
pneumococcus (25,27) did not give any indication for vaccination because this was not a 
specific aim of the studies. The only contraindication to influenza vaccination in HIV-infected 
subjects was age below 6 months (as for healthy children); in addition, the live intranasal 
influenza virus vaccine was contraindicated (1,8). There were minor differences between 
papers on the optimal type of pneumococcal vaccine in relation to patient‟s age. Some authors 
recommended eptavalent conjugate vaccine in children aged  ≤5 years and 23-valent 
pneumococcal polysaccharide vaccine in adolescents and adults, whereas others 
recommended eptavalent pneumococcal conjugate vaccine in children below the age of 2 
years (29). Most guidelines and systematic reviews did not include indications for these 
specific pneumococcal vaccines. Antibody response against vaccines can be lower in the 
presence of severe immunosuppression (CD4+ cell count less than 200 cells/ml) (1,8,25,31). 
However, in the absence of contraindications and of specific side effects, al guidelines 
recommend inactivated influenza and pneumococcal vaccinations in all HIV-infected children 
because of the expected benefits.  
 
 
4.44 Discussion 
 
We have investigated the methodological quality of guidelines and systematic reviews on 
influenza and pneumococcal vaccinations in HIV-infected children using the AGREE 
instrument, a widely accepted instrument designed for this purpose (20, 38-40). Application of 
AGREE has frequently revealed serious methodological flaws in guidelines that are used in 
clinical practice (12-14,39). Recently, the quality of 215 evidence-based pediatric guidelines 
was assessed with AGREE (12). The poorest performance was for the domains “Applicability” 
and “Editorial Independence”. However, overall, pediatrics guidelines scored better than 
guidelines in other fields. For example, no guideline of 11 examined on oral mucositis scored 
>50% in all domains, which equates with a low overall quality (14). In addition, the quality of 
lung cancer guidelines was found to be poor, with only 37% of guidelines recommended for 
use in clinical practice (38). 
Our analysis shows that the quality of most recommendations on influenza and pneumococcal 
vaccinations in HIV-infected children is poor. None of the guideline scored >50% on all 
domains and “Applicability” and “Editorial Independence” were again the weakest fields. Also 
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the “Rigor of Development” domain, which is considered the best indicator of scientific 
quality, scored >50% only in two cases, mainly because most guidelines performed poorly on 
external revision and procedures for updating the guideline. It should be pointed out that when 
no specific information is provided (e.g. methods used in the development process or conflicts 
of interest), the resulting score will be low. Therefore, low scores can be explained by bad 
reporting rather than by an inappropriate development.  
To indirectly support that the mean quality score of consensus statements was similar to that of 
guidelines. This result may be due to the poor quality of guidelines rather than to the high 
quality of consensus statements.  
Similarly to guidelines, the most common weakness of systematic reviews was the unclear, not 
reported or inadequate search strategy. However, most articles classified as reviews were not 
systematic reviews but narrative reviews, which generally do not include a thorough and 
systematic search of papers. Few guidelines graded their recommendations, whereas the 
majority did not and the former obtained higher scores. Guidelines and consensus statements 
recommended by reviewers for use in local practice obtained an AGREE score higher than 
guidelines that were not recommended. For all recommended guidelines except one, the “Rigor 
of Development” domain scored higher than for not recommended guidelines.  
The AGREE instrument is designed only to evaluate the development process of a guideline, 
and not to assess the clinical significant of recommendations. Consequently, a high AGREE 
score does not imply that the recommendation is correct or appropriate (41). However, no 
substantial differences in the evaluation of each appraiser were found; this indicates that the 
judgment of quality was consistent. Despite the methodological limitations, all papers 
recommended influenza and pneumococcal vaccinations for children with HIV infection.  
In conclusion, when drawing-up guidelines for vaccination in HIV-infected patients, much 
more attention should focus on the domains of “Stakeholder Involvement”, “Applicability”, 
“Editorial Independence” and “Rigor of Development”. Our analysis of the weaknesses and 
strengths of guidelines and systematic reviews should alert physicians to the importance of the 
methodological process in developing or implementing a guideline or a systematic review. 
Concomitantly, users should critically evaluate the process leading to a recommendation before 
applying it in clinical practice.  
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5.1 Conclusions 
 
Children with chronic diseases have often a long life. They grow, and become adolescents and 
young adults thanks to improvements of quality of care and progresses in medical treatments.  
A careful understanding of the natural history of HBV and HCV infections in children is 
important in making decisions regarding treatment. Our research shows that chronic hepatitis 
B and C acquired in childhood have a mild and often benign course. Histological analysis 
shows a low prevalence of cirrhosis and a slow progression of fibrosis. Furthermore, a very 
low frequency of liver steatosis was found in chronically HBV-infected children, while a 
higher prevalence o steatosis was found in children with chronic hepatitis C. Conventional 
interferon alpha, lamivudine and adefovir are approved to treat chronic hepatitis B in children. 
The rapid emergence of resistant HBV associated with long-term lamivudine therapy, as well 
as poor tolerability associated with conventional interferon alpha, are factors that should be 
considered before initiating antiviral therapy. To date, it seems reasonable not to treat all 
children, but only those with more-severe liver disease and/or with positive predictive factors 
of response. Treatment of children with chronic HCV infection has provided promising 
results.  
 
Highly active antiretroviral therapy (HAART) has proven effective in controlling clinical 
disease progression and reducing mortality of both adults and children with HIV infection. 
Although HAART has substantially changed the natural history of HIV-1 infection, the 
complex therapeutic regimens require strict adherence. Children growing with HIV face new 
problems related to long-term side effects of therapy, adherence to treatment schedules, 
disclosure of their own or their parents‟ HIV status to other members of community, quality 
of life, and psychosocial problems. The results obtained in this thesis shows that adherence is 
a crucial variable of treatment of AIDS in children and needs early and continuous monitoring 
and implementation. Adherence tends to change over time and, more importantly, children 
non adherence in early stages of life predicts later non adherence, when control of therapy 
may become more difficult or impossible. The caregiver, the relationship between patient and 
physician, and the perception of drug efficacy are key aspects to obtain and maintain 
adherence. The improvement of the psychosocial conditions of HIV-infected patients should 
proceed in parallel with the spectacular progresses that have been made in the clinical, 
immunologic and virologic control of the HIV infection. The identification of needs by means 
the International Classification of Functioning, Disability and Health (ICF), a standardized 
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instrument, may yield essential information for planning health care interventions. ICF 
provides a common tool for assessing the functional status of children and adolescents that 
can increase effective communication between different health care professionals in charge of 
children with HIV.  
 
Public health policies are fundamental to optimize the distribution of resources. Immunization 
should be considered part of the global care of children with chronic medical conditions. 
Strategies are needed at national and regional levels to indicate who should be offered 
vaccinations, how to prioritise target populations, and what are the pathways to ensure rapid 
vaccination in large cohort of subjects. To ensure an effective vaccination policy in at risk 
children, three order of actions should be applied: clear information to families on where to go 
to receive vaccination; coordination of services and physicians involved in the care of 
children to avoid redundancy of vaccination offer; control of immunization performed 
routinely as well as in exceptional circumstances. A suboptimal vaccination rate in at risk 
children may be in part related to a lack of information, fear of side effects of vaccination in 
children who are already ill, to organisational problems and difficulties to identify and call at 
risk subjects. The results presented in this thesis show that the lack of awareness of the 
severity of pneumococcal and influenza infections in at risk children is another reason for the 
low coverage rates 
Immunization includes three different actions: to recommend vaccination, to administer 
vaccine, to check vaccination status. To achieve optimal immunization rates in at risk groups 
a complex array of responsibilities and functions is required. Strategies should differ 
according to the different models of chronic conditions. For diseases principally managed by 
Reference Centres (e.g. HIV infection, chronic liver diseases), physicians of the Reference 
Centres should be in charge for immunization. For diseases with a has a less defined 
management (e.g. neurological disorders), detailed information on vaccination and check of 
vaccination status should be guaranteed by primary care pediatricians.  
Another tool to improve quality of care is the use of practice guidelines. Clinical practice 
guidelines are systematically developed statements to assist practitioners in making decisions 
about appropriate health care in specific clinical circumstances. Their purpose is to make 
explicit recommendations with a definite intent to influence what clinicians do. The primary 
goal of practice guidelines in pediatrics is to improve the health of infants and children by 
ensuring that they receive up-to-date, evidence-based care. Several studies have shown that 
adherence to evidence-based guidelines leads to improvement in the quality of care provided. 
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However, for many health conditions, there is a gap between what medical science has shown 
to be effective practice and what is actually done. The number of guidelines is rapidly 
mounting, also in pediatrics. However, the plethora of guidelines has been accompanied by 
growing concern about differences among guideline recommendations and about the quality 
of guidelines. A well performed guideline should be scientifically valid, usable, reliable, and 
should improve the outcome of patients. But, it is rarely known how a guideline performs in 
clinical practice. Evaluation of guidelines should include both the methods used to develop 
recommendations and the applicability of the recommendations (benefits, adverse effects and 
costs). The analysis of guidelines for vaccination in HIV-infected patients shows weaknesses 
in several domains. Our analysis should alert physicians to the importance of the 
methodological process in developing or implementing a guideline. Concomitantly, users 
should critically evaluate the process leading to a recommendation before applying it in 
clinical practice.  
 
In conclusion, the research presented in this thesis highlights new problems that children with 
chronic diseases have to face, shows some weaknesses of current public health models and  
provide information to improve quality of care of at risk children. Overall, it indicates that the 
rapidly changing pattern of infections on one side, and management on the other should 
promote changes in organization to maximize efficiently and ultimately improve the quality 
of care of high risk children and their families.  
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